<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27877130</article-id><article-id pub-id-type="pmc">5099166</article-id><article-id pub-id-type="doi">10.3389/fphar.2016.00422</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rohleder</surname><given-names>Cathrin</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/140404/overview"/></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Juliane K.</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/381555/overview"/></contrib><contrib contrib-type="author"><name><surname>Lange</surname><given-names>Bettina</given-names></name><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/385606/overview"/></contrib><contrib contrib-type="author"><name><surname>Leweke</surname><given-names>F. M.</given-names></name><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/12366/overview"/></contrib></contrib-group><aff id="aff1"><institution>Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim</institution><country>Germany</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: <italic>Jos&#x000e9; Alexandre Crippa, University of S&#x000e3;o Paulo, Brazil</italic></p></fn><fn fn-type="edited-by"><p>Reviewed by: <italic>Jose M. Trigo, Centre for Addiction and Mental Health, Canada; Fabricio A. Moreira, Federal University of Minas Gerais, Brazil</italic></p></fn><corresp id="fn001">*Correspondence: <italic>F. M. Leweke, <email xlink:type="simple">leweke@cimh.de</email></italic></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>08</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>7</volume><elocation-id>422</elocation-id><history><date date-type="received"><day>29</day><month>7</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Rohleder, M&#x000fc;ller, Lange and Leweke.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Rohleder, M&#x000fc;ller, Lange and Leweke</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetrahydrocannabinol (&#x00394;<sup>9</sup>-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential. Although, results from animal studies are inconsistent to a certain extent and seem to depend on behavioral paradigms, treatment duration and experimental conditions applied, cannabidiol has shown antipsychotic properties in both rodents and rhesus monkeys. After some individual treatment attempts, the first randomized, double-blind controlled clinical trial demonstrated that in acute schizophrenia cannabidiol exerts antipsychotic properties comparable to the antipsychotic drug amisulpride while being accompanied by a superior, placebo-like side effect profile. As the clinical improvement by cannabidiol was significantly associated with elevated anandamide levels, it appears likely that its antipsychotic action is based on mechanisms associated with increased anandamide concentrations. Although, a plethora of mechanisms of action has been suggested, their potential relevance for the antipsychotic effects of cannabidiol still needs to be investigated. The clarification of these mechanisms as well as the establishment of cannabidiol&#x02019;s antipsychotic efficacy and its hopefully benign side-effect profile remains the subject of a number of previously started clinical trials.</p></abstract><kwd-group><kwd>schizophrenia</kwd><kwd>psychosis</kwd><kwd>animal models</kwd><kwd>clinical trials</kwd><kwd>CBD</kwd></kwd-group><counts><fig-count count="0"/><table-count count="4"/><equation-count count="0"/><ref-count count="117"/><page-count count="11"/><word-count count="0"/></counts></article-meta></front><body><sec><title>Introduction</title><p><italic>Cannabis sativa</italic> has been known and used by humans for several 1000 years and the knowledge that it contains an intoxicating principle dates back to 1000 to 1500 B.C. (<xref rid="B1" ref-type="bibr">Adams</xref>, <xref rid="B1" ref-type="bibr">1942</xref>). The two major compounds of cannabis &#x02013; delta-9-tetrahydrocannabinol (&#x00394;<sup>9</sup>-THC) and cannabidiol &#x02013; have been chemically identified in the 1940th (<xref rid="B3" ref-type="bibr">Adams et al., 1940a</xref>,<xref rid="B4" ref-type="bibr">b</xref>,<xref rid="B5" ref-type="bibr">c</xref>; <xref rid="B1" ref-type="bibr">Adams, 1942</xref>; <xref rid="B107" ref-type="bibr">Todd, 1946</xref>). Two decades later, remaining uncertainties regarding the exact position of double bonds were eliminated as new imaging techniques like NMR spectroscopy and X-ray structure determination became available (<xref rid="B84" ref-type="bibr">Mechoulam and Shvo, 1963</xref>; <xref rid="B37" ref-type="bibr">Gaoni and Mechoulam, 1964</xref>; <xref rid="B53" ref-type="bibr">Jones et al., 1977</xref>).</p><p>Along with its chemical identification, &#x00394;<sup>9</sup>-THC has been identified as the major pro-psychotic compound of <italic>Cannabis sativa</italic> (<xref rid="B2" ref-type="bibr">Adams and Baker, 1940</xref>; <xref rid="B4" ref-type="bibr">Adams et al., 1940b</xref>; <xref rid="B6" ref-type="bibr">Allentuck and Bowman, 1942</xref>; <xref rid="B112" ref-type="bibr">Wollner et al., 1942</xref>; <xref rid="B83" ref-type="bibr">Mechoulam et al., 1970</xref>). However, the underlying neurobiological principles remained conjectural until it was observed that cannabinoid drugs inhibit adenylate cyclase activity in neuroblastoma cells (<xref rid="B49" ref-type="bibr">Howlett, 1984</xref>), and the subsequent discovery of the G-protein coupled type 1 cannabinoid receptor (CB<sub>1</sub>R) (<xref rid="B20" ref-type="bibr">Devane et al., 1988</xref>; <xref rid="B80" ref-type="bibr">Matsuda et al., 1990</xref>). A few years later, the type 2 cannabinoid receptor (CB<sub>2</sub>R) (<xref rid="B86" ref-type="bibr">Munro et al., 1993</xref>) as well as the two major endogenous ligands to cannabinoid receptors &#x02013; anandamide (<xref rid="B21" ref-type="bibr">Devane et al., 1992</xref>) and 2-arachidonoyl-<italic>sn</italic>-glycerol (<xref rid="B82" ref-type="bibr">Mechoulam et al., 1995</xref>; <xref rid="B104" ref-type="bibr">Stella et al., 1997</xref>) &#x02013; were discovered. The architecture of the endocannabinoid system (ECS) &#x02013; including endocannabinoids, cannabinoid receptors as well as synthesizing and degrading enzymes &#x02013; has been vividly summarized and illustrated in recent reviews by <xref rid="B77" ref-type="bibr">Lutz et al. (2015)</xref> and <xref rid="B76" ref-type="bibr">Lu and Mackie (2016)</xref>.</p><p>Studies indicating that cannabis abuse might be a stressor for psychotic relapse and exacerbation of schizophrenic symptoms as well as the observation that &#x00394;<sup>9</sup>-THC induced schizophrenia-like neuropsychological and psychopathological alterations in healthy volunteers, led to the hypothesis that a dysfunctional ECS is involved in the etiology of psychoses (<xref rid="B29" ref-type="bibr">Emrich et al., 1997</xref>). In the meantime, several studies reported diverse acute &#x00394;<sup>9</sup>-THC effects in healthy participants and schizophrenic patients, thereby confirming the ECS hypothesis (<xref rid="B69" ref-type="bibr">Leweke et al., 1999</xref>, <xref rid="B68" ref-type="bibr">2000</xref>; <xref rid="B27" ref-type="bibr">D&#x02019;Souza et al., 2004</xref>, <xref rid="B26" ref-type="bibr">2005</xref>; <xref rid="B58" ref-type="bibr">Koethe et al., 2006</xref>; <xref rid="B10" ref-type="bibr">Bhattacharyya et al., 2009</xref>; <xref rid="B35" ref-type="bibr">Fusar-Poli et al., 2009</xref>; <xref rid="B59" ref-type="bibr">Koethe et al., 2009</xref>; <xref rid="B79" ref-type="bibr">Mason et al., 2009</xref>; <xref rid="B99" ref-type="bibr">Sherif et al., 2016</xref>). In addition, several epidemiological studies (for review see, <xref rid="B36" ref-type="bibr">Gage et al., 2016</xref>) substantiated the view that cannabis use has to be considered an important environmental risk factor for the development of schizophrenia in vulnerable individuals. However, the actual lifetime risk seems to be influenced by the dose (<xref rid="B115" ref-type="bibr">Zammit et al., 2002</xref>; <xref rid="B85" ref-type="bibr">Moore et al., 2007</xref>) and frequency of cannabis consumption (<xref rid="B23" ref-type="bibr">Di Forti et al., 2009</xref>), the potency of consumed cannabis preparations (<xref rid="B23" ref-type="bibr">Di Forti et al., 2009</xref>, <xref rid="B24" ref-type="bibr">2014</xref>) and age of onset (<xref rid="B9" ref-type="bibr">Arseneault et al., 2002</xref>).</p><p>While a dysfunctional ECS seems to contribute to the pathophysiology of schizophrenia, the endocannabinoid anandamide is considered to have protective effects by counteracting neurotransmitter imbalances (<xref rid="B65" ref-type="bibr">Leweke, 2012</xref>). Therefore, it has been suggested that modulating the ECS might be a new, promising pharmacological target for schizophrenia.</p><p>To date, two main approaches targeting the ECS have been systematically studied in humans: first, trials using CB<sub>1</sub>R antagonists to treat both psychotic and cognitive symptoms of schizophrenia, and, second, trials using the second most important phytocannabinoid cannabidiol (<xref rid="B66" ref-type="bibr">Leweke et al., 2016</xref>). In addition, a single clinical case series on dronabinol (&#x00394;<sup>9</sup>-THC) in treatment-refractory severe chronic schizophrenia has been conducted (<xref rid="B98" ref-type="bibr">Schwarcz et al., 2009</xref>).</p><p>In contrast to &#x00394;<sup>9</sup>-THC, cannabidiol appears to have no psychotomimetic potential, but shows antipsychotic effects in rodents and humans. Thus, this review focuses on (1) preclinical studies investigating cannabidiol as a potential antipsychotic in animal models of aspects of schizophrenia, (2) clinical evidence for its antipsychotic action, and, (3) potential mechanisms of action and their potential relevance for the antipsychotic effects of cannabidiol.</p></sec><sec><title>Methods</title><p>We conducted a PubMed search up to and including June 28, 2016, using the search terms cannabidiol AND (antipsychotic OR schizophrenia OR psychosis). Identified references were scanned for clinical trials with schizophrenic patients as well as studies with animal models of aspects of schizophrenia, analyzing the effects of cannabidiol on negative symptoms and cognitive deficits. Studies restricted to analysis of locomotor activity or anxiety were not considered. In addition, we used the search term cannabidiol AND targets to scan for reports on the possible mode of action.</p></sec><sec><title>Antipsychotic Potential Of Cannabidiol: Insights From Preclinical Studies</title><p>Schizophrenia is characterized by heterogeneous symptoms that can be grouped into three main symptom categories: (1) positive symptoms (delusions, thought disorder, hallucinations), (2) negative symptoms (anhedonia, blunted affect, social withdrawal) and (3) cognitive impairment (sensory information processing, attention, working memory, executive functions) (<xref rid="B33" ref-type="bibr">Freedman, 2003</xref>; <xref rid="B113" ref-type="bibr">Wong and Van Tol, 2003</xref>). These main symptoms are often accompanied by more unspecific symptoms like anxiety (<xref rid="B33" ref-type="bibr">Freedman, 2003</xref>).</p><p>Although psychotic symptoms are human specific to a large extent, animal models are able to provide insight into certain aspects of schizophrenia, including negative symptoms [e.g., inadequate social behavior/social withdrawal, sensorimotor gating deficits as measured by prepulse inhibition (PPI)], cognitive impairments (e.g., working memory deficits) or anxiety. Thus, these animal models for aspects of schizophrenia can be used to investigate the antipsychotic potential of new drugs like cannabidiol on negative and cognitive symptoms. As available antipsychotics do not sufficiently ameliorate negative symptoms and cognitive impairments (<xref rid="B46" ref-type="bibr">Hanson et al., 2010</xref>), these studies can make an important contribution.</p><p>Schizophrenia is not only characterized by a heterogeneous combination of symptoms but also by a heterogeneous etiology (<xref rid="B16" ref-type="bibr">Cannon and Jones, 1996</xref>; <xref rid="B13" ref-type="bibr">Brown, 2011</xref>; <xref rid="B56" ref-type="bibr">Kahn et al., 2015</xref>). This led to the development of animal models based on different etiological factors of schizophrenia. In the following, the concepts of animal models used to study the effects of cannabidiol are summarized in brief.</p><p>As mentioned above, cannabis use is regarded as one important risk factor for the development of schizophrenia. Hence, animal models of early cannabis exposure are used to investigate the long-lasting behavioral consequences of cannabis use and to clarify the underlying cellular mechanisms (<xref rid="B96" ref-type="bibr">Rubino and Parolaro, 2016</xref>). However, based on the observation that cannabis preparations or single cannabinoids like &#x00394;<sup>9</sup>-THC induce psychotic-like symptoms in healthy volunteers (for review see <xref rid="B99" ref-type="bibr">Sherif et al., 2016</xref>), acute cannabinoid administration is also used to mimic schizophrenia-like symptoms in rodents.</p><p>Furthermore, based on the hypothesis that disrupted glutamatergic neurotransmission contributes to the development of schizophrenia (<xref rid="B57" ref-type="bibr">Kim et al., 1980</xref>), pharmacological and genetic glutamatergic models have been used in cannabidiol research. Since this dysfunction is characterized by hypofunctional <italic>N</italic>-methyl-<sc>D</sc>-aspartic acid (NMDA) receptors (for review see <xref rid="B101" ref-type="bibr">Snyder and Gao, 2013</xref>), for example, NMDA receptor antagonists like MK-801 are administered to mimic schizophrenic-like symptoms in rodents. The genetic model is based on <italic>neuregulin 1</italic>, a susceptibility gene for schizophrenia (<xref rid="B103" ref-type="bibr">Stefansson et al., 2002</xref>). <italic>Neuregulin 1</italic> is involved in neuronal migration, influences myelination and regulates expression of NMDA, &#x003b3;-aminobuytric acid receptor A (GABA<sub>A</sub>) as well as acetylcholin receptor subunits (for review see <xref rid="B17" ref-type="bibr">Corfas et al., 2004</xref>). Heterozygous transmembrane <italic>Neuregulin 1</italic> mutant mice (<italic>Nrg1</italic> TM HET) seem to have fewer functional NMDA receptors (<xref rid="B103" ref-type="bibr">Stefansson et al., 2002</xref>), a region-specific alteration of NMDA receptor expression as well as decreased dopamine D<sub>2</sub> receptor binding in the striatum (<xref rid="B87" ref-type="bibr">Newell et al., 2013</xref>). Interestingly, the CB<sub>1</sub> receptor density is comparable to the density in wild type animals except for a slight increase within the striatum of <italic>Nrg1</italic> TM HET (<xref rid="B87" ref-type="bibr">Newell et al., 2013</xref>).</p><p>The spontaneously hypertensive rat (SHR) strain has also been suggested as a model for aspects of schizophrenia. These rats show impaired social interaction (<xref rid="B14" ref-type="bibr">Calzavara et al., 2011</xref>; <xref rid="B8" ref-type="bibr">Almeida et al., 2014</xref>) and reduced PPI (<xref rid="B63" ref-type="bibr">Levin et al., 2011</xref>, <xref rid="B64" ref-type="bibr">2014</xref>) as compared to Wistar rats. In addition, antipsychotic drugs reduced abnormalities in contextual fear conditioning (<xref rid="B15" ref-type="bibr">Calzavara et al., 2009</xref>), social interaction (<xref rid="B14" ref-type="bibr">Calzavara et al., 2011</xref>) as well as PPI (<xref rid="B63" ref-type="bibr">Levin et al., 2011</xref>). Nevertheless, other studies observed an increased PPI compared to Sprague Dawely rats (<xref rid="B109" ref-type="bibr">van den Buuse, 2004</xref>) or an increased social interaction behavior toward Wistar-Kyoto rats (<xref rid="B48" ref-type="bibr">Hopkins et al., 2009</xref>).</p><sec><title>Effects of Cannabidiol on Social Behavior</title><p>Social withdrawal is a key negative symptom of schizophrenia. Thus, several studies investigated the effects of cannabidiol on social behavior in different rodent animal models for schizophrenia (<bold>Table <xref ref-type="table" rid="T1">1</xref></bold>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Animal studies evaluating the effects of cannabidiol (CBD) on social behavior.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Animal model</th><th valign="top" align="left" rowspan="1" colspan="1">Treatment regimen and test procedure</th><th valign="top" align="center" rowspan="1" colspan="1">Effective dose [/kg]</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Spontaneously hypertensive rats (SHR)</td><td valign="top" align="left" rowspan="1" colspan="1">1, 5, 15, 30, or 60 mg/kg CBD, i.p. injection 30 min prior to social interaction test</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B7" ref-type="bibr">Almeida et al., 2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (acute, 0.3 or 0.6 mg/kg), male Sprague Dawley rats</td><td valign="top" align="left" rowspan="1" colspan="1">1 or 3 mg/kg CBD, i.p. injection 20 min prior to MK-801 administration. Social interaction test started 20 min after the last injection</td><td valign="top" align="center" rowspan="1" colspan="1">3, 10 (partially)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B42" ref-type="bibr">Gururajan et al., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (acute, 0.3 mg/kg), male Sprague Dawley rats</td><td valign="top" align="left" rowspan="1" colspan="1">1 or 3 mg/kg CBD, i.p. injection 20 min prior to MK-801 administration. A modified social interaction test started 20 min after the last injection</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B43" ref-type="bibr">Gururajan et al., 2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (chronic: 1 mg/kg, 28 days), male C57BL/6J mice</td><td valign="top" align="left" rowspan="1" colspan="1">30 or 60 mg/kg CBD, i.p. injection 30 min prior to social interaction test</td><td valign="top" align="center" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B40" ref-type="bibr">Gomes et al., 2015b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (acute, 0.08 mg/kg), male Wistar rats</td><td valign="top" align="left" rowspan="1" colspan="1">5, 12, or 30 mg/kg CBD, i.p. injection 30 min prior to MK-801 administration. Social interaction/recognition test started 30 min after the last injection</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B19" ref-type="bibr">Deiana et al., 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male <italic>Nrg1</italic> TM HET mice</td><td valign="top" align="left" rowspan="1" colspan="1">Chronic treatment with 1, 50, or 100 mg/kg CBD over 3 weeks</td><td valign="top" align="center" rowspan="1" colspan="1">50 (partially 1 and 100)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B74" ref-type="bibr">Long et al., 2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x00394;<sup>9</sup>-THC (1 mg/kg), male Sprague Dawley rats</td><td valign="top" align="left" rowspan="1" colspan="1">5 or 20 mg/kg CBD, i.p. injection 20 min prior to &#x00394;<sup>9</sup>-THC administration. Social interaction test started 20 min after the last injection</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B78" ref-type="bibr">Malone et al., 2009</xref></td></tr></tbody></table></table-wrap><p>Cannabidiol (dosage range: 1&#x02013;50 mg/kg) itself seems to have no effect on social interaction of untreated Sprague Dawley (<xref rid="B78" ref-type="bibr">Malone et al., 2009</xref>; <xref rid="B43" ref-type="bibr">Gururajan et al., 2012</xref>), Wistar rats (<xref rid="B110" ref-type="bibr">van Ree et al., 1984</xref>; <xref rid="B19" ref-type="bibr">Deiana et al., 2015</xref>), C57BL/6JArc mice (<xref rid="B73" ref-type="bibr">Long et al., 2010</xref>; <xref rid="B40" ref-type="bibr">Gomes et al., 2015b</xref>), and wild type-like littermates of <italic>Nrg1</italic> TM HET mice (<xref rid="B74" ref-type="bibr">Long et al., 2012</xref>). However, in Wistar rats 1 mg/kg cannabidiol increased social interaction behavior, whereas higher dosages (5, 15, 30, 60 mg/kg) had no effect (<xref rid="B7" ref-type="bibr">Almeida et al., 2013</xref>). In addition, impaired social memory was observed in Wistar rats (<xref rid="B19" ref-type="bibr">Deiana et al., 2015</xref>) after acute cannabidiol administration (12 and 30 mg/kg, but not 5 mg/kg).</p><p>The majority of studies reported that cannabidiol was able to attenuate or reverse induced altered social behavior. Pretreatment with 20 mg/kg cannabidiol reversed the effects of 1 mg/kg &#x00394;<sup>9</sup>-THC (<xref rid="B78" ref-type="bibr">Malone et al., 2009</xref>), while 3 mg/kg cannabidiol inhibited the effects on social investigative behavior of acute MK-801 treatment in a modified social interaction task, increasing it significantly beyond control level (<xref rid="B43" ref-type="bibr">Gururajan et al., 2012</xref>). This is in line with the previous finding of the group that cannabidiol (3, 10 mg/kg) partially inhibited MK-801-induced social withdrawal in a classical social interaction paradigm (<xref rid="B42" ref-type="bibr">Gururajan et al., 2011</xref>). In mice, pretreatment with 60 mg/kg cannabidiol was found to reverse impaired social interaction induced by chronic MK-801 treatment, while a lower cannabidiol dose (30 mg/kg) attenuated the effects of MK-801 only by trend (<xref rid="B40" ref-type="bibr">Gomes et al., 2015b</xref>). As the antipsychotic clozapine also inhibited MK-801 effects on social investigative behavior, it has been suggested that cannabidiol might also be effective in schizophrenia patients showing inadequate social behaviors (<xref rid="B43" ref-type="bibr">Gururajan et al., 2012</xref>; <xref rid="B40" ref-type="bibr">Gomes et al., 2015b</xref>). However, cannabidiol did not reverse the social recognition impairments induced by an acute low-dose injection of MK-801 in Wistar rats. Furthermore, cannabidiol was not able to elevate the decreased social interaction of SHR rats (<xref rid="B7" ref-type="bibr">Almeida et al., 2013</xref>).</p><p>Although, <italic>Nrg1</italic> TM HET mutant mice showed similar social behavior compared to their wild type-like littermates (<xref rid="B74" ref-type="bibr">Long et al., 2012</xref>), chronic cannabidiol treatment (50 mg/kg, 21 days) increased social interaction as well as specific social behaviors like nosing and anogenital sniffing in mutant mice but not in wild type mice. A higher cannabidiol dose (100 mg/kg) solely increased anogenital-sniffing duration in mutant mice, while lower concentrations (1 mg/kg) led only to increasing nosing frequencies.</p><p>Taken together, cannabidiol showed antipsychotic properties in glutamatergic animal models as well as in a model targeting the ECS, whereas it has been ineffective in SHR rats.</p></sec><sec><title>Effects of Cannabidiol on Prepulse Inhibition</title><p>Prepulse inhibition of the acoustic startle response is a neuropsychological process during which a weak sensory stimulus &#x02013; prepulse &#x02013; attenuates the motor response to a subsequent strong startling stimulus (<xref rid="B95" ref-type="bibr">Rohleder et al., 2016</xref>). Since PPI impairments are observed in schizophrenia patients and PPI can be reliably assessed in both animals and humans, it has been used as behavioral measure of aspects of schizophrenia. Unfortunately, results from rodent studies analyzing the effects of cannabidiol on PPI and acoustic startle response in animal models of schizophrenia and untreated control rodents are inconsistent to a certain extent (<bold>Table <xref ref-type="table" rid="T2">2</xref></bold>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Animal studies evaluating the effects of cannabidiol (CBD) on prepulse inhibition (PPI).</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Animal model</th><th valign="top" align="left" rowspan="1" colspan="1">Treatment regimen and test procedure</th><th valign="top" align="center" rowspan="1" colspan="1">Effective dose [mg/kg]</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Spontaneously hypertensive rats (SHR)</td><td valign="top" align="left" rowspan="1" colspan="1">15, 30, or 60 mg/kg CBD, i.p. 30 min prior to PPI paradigm</td><td valign="top" align="center" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B64" ref-type="bibr">Levin et al., 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (acute, 0.3 or 0.6 mg/kg), male Sprague Dawley rats</td><td valign="top" align="left" rowspan="1" colspan="1">3, 10, or 30 mg/kg CBD, i.p. injection 20 min prior to MK-801 administration. PPI paradigm started 20 min after the last injection</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B42" ref-type="bibr">Gururajan et al., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (chronic: 1 mg/kg, 28 days), male C57BL/6J mice</td><td valign="top" align="left" rowspan="1" colspan="1">30 or 60 mg/kg CBD, i.p. treatment began on 6th day of MK-801 administration. PPI paradigm was conducted on day 29</td><td valign="top" align="center" rowspan="1" colspan="1">30, 60</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B39" ref-type="bibr">Gomes et al., 2015a</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (acute, 1 mg/kg), male C57BL/6J mice</td><td valign="top" align="left" rowspan="1" colspan="1">5 mg/kg CBD, i.p. injection 20 min prior to MK-801 administration. PPI paradigm started 5 min after the last injection</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B75" ref-type="bibr">Long et al., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male <italic>Nrg1</italic> TM HET mice</td><td valign="top" align="left" rowspan="1" colspan="1">1, 50, or 100 mg/kg CBD, i.p. over 21 days. PPI paradigm was done 30&#x02013;45 min after the first injection and on day 21</td><td valign="top" align="center" rowspan="1" colspan="1">100 (acute)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B74" ref-type="bibr">Long et al., 2012</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Amphetamine (acute, 10 mg/kg) male Swiss mice</td><td valign="top" align="left" rowspan="1" colspan="1">15, 30, or 60 mg/kg CBD, i.p. 30 min prior to amphetamine injection. PPI paradigm started 30 min after the last injection</td><td valign="top" align="center" rowspan="1" colspan="1">15, 30, 60</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B89" ref-type="bibr">Pedrazzi et al., 2015</xref></td></tr></tbody></table></table-wrap><p>The effects of cannabidiol on startle amplitude and PPI of healthy rodents seem to be not only dose- but also strain- and species-dependent. In male Swiss mice, cannabidiol (15, 30, or 60 mg/kg) did not affect PPI or startle amplitude (<xref rid="B89" ref-type="bibr">Pedrazzi et al., 2015</xref>). On the other hand, <xref rid="B75" ref-type="bibr">Long et al. (2006)</xref> reported that C57BL/6JArc mice acutely treated with cannabidiol (1 and 15, but not 5 mg/kg) showed increased startle amplitudes while PPI remained unaffected. In contrast, in wild type-like littermates of <italic>Nrg1</italic> TM HET mice, acute treatment with low concentrations of cannabidiol (1 and 50 mg/kg) as well as chronic cannabidiol treatment (1, 50, 100 mg/kg; 21 days) had no effect on startle amplitude and PPI, but acute administration of a high cannabidiol dosage (100 mg/kg) resulted in an increased startle amplitude (<xref rid="B74" ref-type="bibr">Long et al., 2012</xref>).</p><p>Such heterogeneous results were also observed in healthy rats. In Sprague Dawley rats, cannabidiol reduced startle amplitude (3 and 10 but not 30 mg/kg) and PPI (10 mg/kg only) in a dose-dependent manner (<xref rid="B42" ref-type="bibr">Gururajan et al., 2011</xref>), whereas the startle amplitude of Wistar rats was not influenced by acute cannabidiol (15, 30, 60 mg/kg) treatment, while higher dosages of cannabidiol (30, 60 mg/kg) seemed to increase PPI (<xref rid="B64" ref-type="bibr">Levin et al., 2014</xref>).</p><p>Interestingly, animals with transmembrane <italic>Neuregulin 1</italic> mutation, representing a genetic glutamatergic schizophrenia model, showed similar startle amplitude and PPI compared to their wild type like littermates. However, acute administration of 100 mg/kg cannabidiol increased not only the startle amplitude as observed in wild type like littermates, but also PPI. On the other hand, chronic cannabidiol treatment (1, 50, 100 mg/kg; 21 days) had no effect on startle amplitude and PPI in <italic>Nrg1</italic> TM HET or their wild type like littermates (<xref rid="B74" ref-type="bibr">Long et al., 2012</xref>).</p><p>Pharmacological studies mimicking glutamatergic deficits of schizophrenia revealed that pretreatment with cannabidiol (5 mg/kg) reversed PPI disruption in C57BL/6JArc mice (<xref rid="B75" ref-type="bibr">Long et al., 2006</xref>). In addition, chronic cannabidiol treatment (30 or 60 mg/kg) attenuated PPI impairments induced by chronic MK-801 administration in C57BL/6J mice (<xref rid="B39" ref-type="bibr">Gomes et al., 2015a</xref>). While cannabidiol seems to be efficacious in treating PPI impairments in mice, pretreatment with cannabidiol had no effect on PPI deficits induced by acute MK-801-injection in Sprague Dawley rats (<xref rid="B42" ref-type="bibr">Gururajan et al., 2011</xref>).</p><p>However, acute cannabidiol treatment also reversed PPI deficits in two other animal models of aspects of schizophrenia. First, cannabidiol (30 mg/kg) reversed PPI deficit of SHR rats but had no effects on their reduced startle amplitude (<xref rid="B64" ref-type="bibr">Levin et al., 2014</xref>). Second, cannabidiol (15, 30, or 60 mg/kg) attenuated the amphetamine-disruptive effects on PPI in male Swiss mice (<xref rid="B89" ref-type="bibr">Pedrazzi et al., 2015</xref>). Interestingly, the inhibition of anandamide hydrolysis by URB597 [selective fatty acid amide hydrolase (FAAH) inhibitor] had the same effect. Hence, the authors suggested that an increase of anandamide availability might be involved in the beneficial effects of cannabidiol.</p><p>In a nutshell, various studies showed that cannabidiol partially affected startle amplitude and PPI in healthy animals, while it had no effects in rats treated with MK-801, but reversed the PPI disruptive effects of MK-801 and amphetamine in mice as well as the PPI deficit of SHR rats.</p><p>These discrepancies, observed in both healthy wild type animals and animal models for aspects of schizophrenia, might be related to the different species/strain or experimental conditions applied. Therefore, more studies clarifying the potential antipsychotic effect of cannabidiol with regard to this specific behavioral deficit are desirable.</p></sec><sec><title>Effect of Cannabidiol on Working Memory</title><p>Various paradigms are available to test cognitive performance in animals. Two studies investigating the effects of cannabidiol on cognitive performance in &#x00394;<sup>9</sup>-THC- or MK-801-treated animals, respectively, used paradigms based on object and/or spatial recognition. In addition, two further studies investigated the effects of cannabidiol-rich cannabis extracts in a spatial recognition task (<bold>Table <xref ref-type="table" rid="T3">3</xref></bold>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Animal studies evaluating the effects of cannabidiol (CBD) on working memory.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Animal model</th><th valign="top" align="left" rowspan="1" colspan="1">Treatment regimen and test procedure</th><th valign="top" align="center" rowspan="1" colspan="1">Effective dose [mg/kg]</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (chronic: 1 mg/kg, 28 days), male C57BL/6J mice</td><td valign="top" align="left" rowspan="1" colspan="1">30 or 60 mg/kg CBD, i.p. injection 30 min prior to novel object recognition test</td><td valign="top" align="center" rowspan="1" colspan="1">30, 60</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B40" ref-type="bibr">Gomes et al., 2015b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x00394;<sup>9</sup>-THC (0.2, 0.5 mg/kg i.m.), male adults rhesus monkeys</td><td valign="top" align="left" rowspan="1" colspan="1">0.5 mg/kg CBD, i.m. concurrently with &#x00394;<sup>9</sup>-THC administration. Visuospatial Paired Associates Learning task and Self-Ordered Spatial Search started 30 min after the injections</td><td valign="top" align="center" rowspan="1" colspan="1">0.5 (task selective)</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B114" ref-type="bibr">Wright et al., 2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x00394;<sup>9</sup>-THC-rich and CBD-rich cannabis extracts, male, adult Lister rats</td><td valign="top" align="left" rowspan="1" colspan="1">CBD-rich cannabis extracts (0.5, 5, 10, or 50 mg/kg CBD and up to 4 mg/kg &#x00394;<sup>9</sup>-THC), i.p. 30 min prior to Delayed Matching to Sample task. In addition, CBD-rich cannabis extracts were simultaneously injected with &#x00394;<sup>9</sup>-THC-rich cannabis extract injection</td><td valign="top" align="center" rowspan="1" colspan="1">50 (as it contained nearly 4 mg/kg &#x00394;<sup>9</sup>-THC</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B30" ref-type="bibr">Fadda et al., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MK-801 (0.1 mg/kg, acute), male, adult Lister rats</td><td valign="top" align="left" rowspan="1" colspan="1">CBD-rich cannabis extracts (5 or 10 mg/kg CBD), i.p. concurrently with MK-801 injection, 30 min prior to Delayed Matching to Sample task. In addition, CBD-rich cannabis extracts were simultaneously injected with &#x00394;<sup>9</sup>-THC-rich cannabis extract injection</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B31" ref-type="bibr">Fadda et al., 2006</xref></td></tr></tbody></table></table-wrap><p>The visuospatial Paired Associates Learning task (vsPAL) and the Self-Ordered Spatial Search (SOSS) task belong to the category of spatial recognition tasks that are frequently used in non-human primates. In rhesus monkeys, acute intramuscular &#x00394;<sup>9</sup>-THC administration (0.2 and 0.5 mg/kg) impaired overall trial completion accuracy and percent completed trials in the vsPAL with increasing trial-difficulty as well as trial completion accuracy in the SOSS task (<xref rid="B114" ref-type="bibr">Wright et al., 2013</xref>). Cannabidiol itself had no effect on cognitive performance. Interestingly, co-treatment with cannabidiol reversed the effects of &#x00394;<sup>9</sup>-THC on vsPAL, but did not affect &#x00394;<sup>9</sup>-THC-induced SOSS deficits.</p><p>These results are in line with a study assessing the effects of cannabidiol on novel object recognition (NOR) impairments in mice. The NOR task is often used in rodents and partially resembles vsPAL. While in vsPAL a familiar object and its former position has to be identified, NOR evaluates whether the animal recognizes a new unfamiliar object, as rodents tend to explore new objects more intensively than familiar ones. Cannabidiol (30 or 60 mg/kg) significantly reversed the NOR performance impairments observed in male C57BL/6J mice chronically treated with MK-801, but had no effect <italic>per se</italic> (<xref rid="B40" ref-type="bibr">Gomes et al., 2015b</xref>).</p><p>Furthermore, <xref rid="B30" ref-type="bibr">Fadda et al. (2004</xref>, <xref rid="B31" ref-type="bibr">2006</xref>) investigated the effects of cannabidiol-rich cannabis extracts in a water maze based delayed-matching-to-position task (DMTP). In the first trial, animals were placed onto a platform. In the second trial animals were released into the water and had to find the platform again. Cannabidiol-rich cannabis extracts did not affect the spatial working memory of rats, although these extracts also contained &#x00394;<sup>9</sup>-THC. In particular the highest dose of 50 mg/kg cannabidiol-rich extracts contained nearly 4 mg/kg &#x00394;<sup>9</sup>-THC, a dose that was sufficient to impair the working memory when given alone. Thus, the authors concluded that cannabidiol is able to antagonize the cognitive impairment. However, the cannabidiol-rich extracts did not reverse memory deficits when administered concurrently with the &#x00394;<sup>9</sup>-THC-rich cannabis extracts. Therefore, it has been suggested, that the cannabidiol/&#x00394;<sup>9</sup>-THC ratio was not high enough to be effective (<xref rid="B30" ref-type="bibr">Fadda et al., 2004</xref>).</p><p>Interestingly, cannabidiol-rich extracts (5 and 10 mg/kg) were also unable to reverse working memory deficits induced by MK-801 in rats (<xref rid="B31" ref-type="bibr">Fadda et al., 2006</xref>). It might be that the cannabidiol dosage had simply been too low, as higher concentrations (30 or 60 mg/kg) had been shown to be effective in mice (<xref rid="B40" ref-type="bibr">Gomes et al., 2015b</xref>). However, even higher dosages of cannabidiol may not reverse working memory deficits induced by MK-801 in rats due to interspecies differences.</p><p>Overall, the limited data available seem to suggest that cannabidiol has potential in ameliorating not only negative symptoms but also cognitive functions. However, as task-selective differences were observed, its effectiveness might be restricted to certain aspects of cognitive functions. Therefore, further studies analyzing the effects of cannabidiol on various cognitive aspects are called for.</p></sec></sec><sec><title>Antipsychotic Potential Of Cannabidiol: Evidence From Clinical Studies</title><p>The results of the first individual treatment attempt with cannabidiol were reported in <xref rid="B117" ref-type="bibr">Zuardi et al. (1995)</xref>. Daily administration of up to 1500 mg/day over 4 weeks resulted in decreased scores on the Brief Psychiatric Rating Scale (BPRS) and Interactive Observation Scale for Psychiatric Inpatients (IOSPI), indicating an overall improvement of psychotic symptoms. Interestingly, the clinical improvement was not increased by additional treatment with haloperidol, a first generation antipsychotic. Nearly 10 years later, <xref rid="B116" ref-type="bibr">Zuardi et al. (2006)</xref> published a small case series of three patients. They were treated with increasing doses of cannabidiol (maximum 1280 mg/kg) over 30 days. Importantly, one of these patients showed a slight improvement of both positive and negative symptoms. Interestingly, no side effects were reported in patients treated with cannabidiol. The first controlled, randomized, double-blind clinical trial was conducted by <xref rid="B67" ref-type="bibr">Leweke et al. (2012)</xref>. During this 4-week trial 42 schizophrenic patients received either cannabidiol (600&#x02013;800 mg/day) or amisulpride (600&#x02013;800 mg/day) &#x02013; a highly effective second generation antipsychotic, selectively antagonizing D<sub>2/3</sub> receptors (<xref rid="B62" ref-type="bibr">Leucht et al., 2002</xref>). Both drugs resulted in significant clinical improvement of both positive and negative symptoms of psychosis. The efficacy of cannabidiol was comparable to that of amisulpride, but, importantly, cannabidiol revealed a superior side effect profile when compared to amisulpride. In particular, cannabidiol did not induce prolactin increase, weight gain, or extrapyramidal symptoms. Interestingly, in patients randomly allocated to cannabidiol treatment, the reduction of psychotic symptoms was significantly associated with an increase of anandamide levels in serum. This was exclusive for the cannabidiol treatment group and is in support for the hypothesis that cannabidiol&#x02019;s antipsychotic effect is at least in part mediated via anandamide and potentially related to a block of its metabolization or uptake.</p><p>As reviewed in <xref rid="B66" ref-type="bibr">Leweke et al. (2016)</xref>, four additional clinical trials with schizophrenic patients have been initiated so far. Although to date data have not been published in a peer reviewed process, the sponsor of one recent clinical trial investigating the antipsychotic effects of cannabidiol (GW42003, 1000 mg/day) as add-on medication in 88 patients suffering from schizophrenia or related disorders (e.g., schizoaffective or schizophrenia-like disorder) over a period of 6 weeks, announced that cannabidiol was consistently superior to placebo with regard to psychopathology while at the same time showing no relevant side-effect profile (<xref rid="B44" ref-type="bibr">GW Pharmaceuticals plc, 2015</xref>).</p><p>While cannabidiol seems to develop antipsychotic properties during at least 4 weeks of treatment, acute administration of cannabidiol (300 or 600 mg/kg) did not affect selective attention studied in 28 schizophrenic outpatients (regularly treated with antipsychotics) using the Stroop Color Word Test (<xref rid="B45" ref-type="bibr">Hallak et al., 2010</xref>). However, there also were no side effects reported.</p><p>Although, only few data on the antipsychotic potential in schizophrenic patients are currently available (summarized in <bold>Table <xref ref-type="table" rid="T4">4</xref></bold>), they consistently indicate a promising efficacy and favorable side-effect profile of cannabidiol. However, large-scale clinical trials are still needed to evaluate the long-term efficacy and safety of this putative new antipsychotic.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Published clinical trials and case series evaluating the effects of cannabidiol in schizophrenic patients.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Design</th><th valign="top" align="left" rowspan="1" colspan="1">Primary efficacy endpoint</th><th valign="top" align="left" rowspan="1" colspan="1">Outcome</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Single case report, open-label, treatment-resistant schizophrenia, up to 1500 mg/day CBD over 4 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">Psychotic symptoms (BPRS; IOSPI)</td><td valign="top" align="left" rowspan="1" colspan="1">Improvement in a treatment-resistant patient</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B117" ref-type="bibr">Zuardi et al., 1995</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Open-label, case series (three patients), treatment-resistant schizophrenia, up to 1280 mg/day CBD over 30 days</td><td valign="top" align="left" rowspan="1" colspan="1">Psychotic symptoms (BPRS)</td><td valign="top" align="left" rowspan="1" colspan="1">One patient showed mild improvement in positive and negative symptoms</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B116" ref-type="bibr">Zuardi et al., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Double-blind, active controlled acute trial, single CBD (300 or 600 mg) or placebo administration</td><td valign="top" align="left" rowspan="1" colspan="1">Stroop Color Word Test (SCWT)</td><td valign="top" align="left" rowspan="1" colspan="1">No beneficial effects of single CBD administration on cognitive performance of schizophrenic patients</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B45" ref-type="bibr">Hallak et al., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Double-blind, active-controlled RCT with 42 acute schizophrenic patients, 600&#x02013;800 mg/day over 4 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">Psychotic symptoms (PANSS/BPRS)</td><td valign="top" align="left" rowspan="1" colspan="1">Significant clinical improvement compared to baseline on days 14 and 28 for CBD and amisulpride. Superior side-effect profile for CBD compared to amisulpride</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B67" ref-type="bibr">Leweke et al., 2012</xref></td></tr></tbody></table><table-wrap-foot><attrib><italic>BPRS, Brief Psychiatric Rating Scale; CBD, cannabidiol; IOSPI, Interactive Observation Scale for Psychiatric Inpatients; PANSS, Positive and Negative Syndrome Scale; RCT, randomized clinical trial.</italic></attrib></table-wrap-foot></table-wrap></sec><sec><title>Cannabidiol: Potential Mechanism Of Action</title><p>The mode of action of cannabidiol is still not fully understood, although a plethora of possible mechanisms have been proposed.</p><p>Cannabidiol and &#x00394;<sup>9</sup>-THC are the most important phytocannabinoids in the cannabis plant. Therefore, it has been hypothesized that both compounds might have the same molecular target, the cannabinoid receptors. However, several binding studies showed that cannabidiol has no significant affinity at CB<sub>1</sub>R and CB<sub>2</sub>R (<xref rid="B20" ref-type="bibr">Devane et al., 1988</xref>; <xref rid="B100" ref-type="bibr">Showalter et al., 1996</xref>; <xref rid="B106" ref-type="bibr">Thomas et al., 1998</xref>; <xref rid="B11" ref-type="bibr">Bisogno et al., 2001</xref>; <xref rid="B52" ref-type="bibr">Jones et al., 2010</xref>). In addition, most efficacy studies found no explicit receptor response (<xref rid="B80" ref-type="bibr">Matsuda et al., 1990</xref>; <xref rid="B91" ref-type="bibr">Petitet et al., 1998</xref>; <xref rid="B12" ref-type="bibr">Breivogel et al., 2001</xref>; <xref rid="B52" ref-type="bibr">Jones et al., 2010</xref>). In fact, it has been reported that cannabidiol acts as an antagonist of CB<sub>1</sub>R agonists such as WIN-55212 and CP-55940 (<xref rid="B91" ref-type="bibr">Petitet et al., 1998</xref>; <xref rid="B90" ref-type="bibr">Pertwee et al., 2002</xref>; <xref rid="B105" ref-type="bibr">Thomas et al., 2007</xref>). As cannabidiol also inhibited internalization of CB<sub>1</sub>R (<xref rid="B61" ref-type="bibr">Laprairie et al., 2014</xref>), it has been hypothesized that the observed antagonistic activity might be based on negative allosteric modulation of CB<sub>1</sub>R rather than on orthosteric binding (<xref rid="B60" ref-type="bibr">Laprairie et al., 2015</xref>). Consistent with these findings, <xref rid="B60" ref-type="bibr">Laprairie et al. (2015)</xref> provided evidence that <italic>in vitro</italic> cannabidiol behaves as a non-competitive negative allosteric modulator of CB<sub>1</sub>R.</p><p>Owing to the observed significant association of the antipsychotic effect of cannabidiol with an increase of anandamide levels in serum (<xref rid="B67" ref-type="bibr">Leweke et al., 2012</xref>), it has been hypothesized that cannabidiol exerts its antipsychotic properties by moderately blocking FAAH, resulting in an inhibition of anandamide and of related fatty acid ethanolamide (palmitoylethanolamide and oleoylethanolamide) degradation. <italic>In vitro</italic>, cannabidiol inhibited FAAH in mouse neuroblastoma cell (N18TG2) membrane preparations (<xref rid="B11" ref-type="bibr">Bisogno et al., 2001</xref>), mouse brain microsomes (<xref rid="B111" ref-type="bibr">Watanabe et al., 1996</xref>), as well as homogenates of rat brain membranes (<xref rid="B18" ref-type="bibr">De Petrocellis et al., 2011</xref>; <xref rid="B67" ref-type="bibr">Leweke et al., 2012</xref>). Moreover, it has been shown that cannabidiol blocks anandamide transporters, since it inhibited anandamide uptake by rat basophilic leukemia cells (RBL-2H3) (<xref rid="B93" ref-type="bibr">Rakhshan et al., 2000</xref>; <xref rid="B11" ref-type="bibr">Bisogno et al., 2001</xref>; <xref rid="B18" ref-type="bibr">De Petrocellis et al., 2011</xref>). So far, one possible anandamide transporter, termed FAAH-like anandamide transporter (FLAT) has been identified (<xref rid="B34" ref-type="bibr">Fu et al., 2012</xref>). As FLAT seems to be a splicing variant of the <italic>Faah-1</italic> gene, it may be speculated that cannabidiol binds to similar binding sites of FAAH and FLAT proteins and is able to inhibit both, anandamide degradation and uptake. However, it has recently been reported that cannabidiol does not inhibit the human FAAH enzyme, but binds to fatty acid-binding proteins (FABPs) (<xref rid="B28" ref-type="bibr">Elmes et al., 2015</xref>), which seem to act as intracellular transporters of anandamide and other <italic>N</italic>-acylethanolamines (<xref rid="B54" ref-type="bibr">Kaczocha et al., 2009</xref>, <xref rid="B55" ref-type="bibr">2012</xref>). <xref rid="B28" ref-type="bibr">Elmes et al. (2015)</xref> concluded that cannabidiol reduces anandamide inactivation in humans by competing with anandamide for FABPs binding. As long as FABPs are occupied by cannabidiol, anandamide cannot be transported to the FAAH enzyme, localized on the endoplasmic reticulum, resulting in elevated anandamide levels.</p><p>Although, various other molecular targets have been suggested to contribute to the antipsychotic effects of cannabidiol, their pharmacological relevance still needs to be evaluated in clinical trials.</p><p>On the one hand cannabidiol may facilitate 5-HT<sub>1A</sub> receptor mediated serotonergic neurotransmission. In Chinese hamster ovary (CHO) cells transfected with the human receptor, cannabidiol displaced the 5-HT<sub>1A</sub> receptor agonist [3H]8-OH-DPAT and increased [35S]GTP&#x003b3;S binding (<xref rid="B97" ref-type="bibr">Russo et al., 2005</xref>). On the other hand, cannabidiol did not displace [3H]8-OH-DPAT or stimulate [35S]GTP&#x003b3;S binding in rat brainstem membrane preparations, while it increased the maximal efficacy of 8-OH-DPAT at 100 nmol/L, but not at 1, 10, 31.6 nmol/L or 1 &#x003bc;mol/L (<xref rid="B94" ref-type="bibr">Rock et al., 2012</xref>). Interestingly, in mice, the anticataleptic effect of cannabidiol was prevented by the 5-HT<sub>1A</sub> receptor antagonist WAY100635 (<xref rid="B38" ref-type="bibr">Gomes et al., 2013</xref>; <xref rid="B102" ref-type="bibr">Sonego et al., 2016</xref>). However, it remains unclear, whether the improvement of negative symptoms and cognitive deficits by cannabidiol involves 5-HT<sub>1A</sub> receptor activation, as studies addressing this mechanism are lacking.</p><p>In addition, it has been reported that cannabidiol binds to the peroxisome proliferator-activated receptor gamma (PPAR&#x003b3;) <italic>in vitro</italic> (<xref rid="B88" ref-type="bibr">O&#x02019;Sullivan et al., 2009</xref>; <xref rid="B41" ref-type="bibr">Granja et al., 2012</xref>). PPAR&#x003b3; regulates the expression of genes related to lipid and glucose homeostasis as well as inflammatory responses. Thus, cannabidiol may ameliorate both observed disturbances of glucose metabolism and inflammatory/immune processes in schizophrenic patients (<xref rid="B47" ref-type="bibr">Holmes et al., 2006</xref>; <xref rid="B70" ref-type="bibr">Leza et al., 2015</xref>; <xref rid="B92" ref-type="bibr">Rajasekaran et al., 2015</xref>) by PPAR&#x003b3; activation.</p><p>The activation of transient receptor potential vanilloid type 1 receptors (TRPV1Rs) has also been suggested as mechanism of action, as cannabidiol stimulated TRPV1R in HEK293-cells transiently expressing human (<xref rid="B11" ref-type="bibr">Bisogno et al., 2001</xref>; <xref rid="B71" ref-type="bibr">Ligresti et al., 2006</xref>; <xref rid="B18" ref-type="bibr">De Petrocellis et al., 2011</xref>) or rat TRPV1R (<xref rid="B50" ref-type="bibr">Iannotti et al., 2014</xref>). <italic>In vivo</italic>, it has been shown that pretreatment with TRPV1R antagonist capsazepine blocked the ameliorating effect of cannabidiol on MK-801 induced PPI decrease (<xref rid="B75" ref-type="bibr">Long et al., 2006</xref>), indicating at least a partial involvement of TRPV1R activation. However, capsazepine also blocks calcium channels (<xref rid="B25" ref-type="bibr">Docherty et al., 1997</xref>) and nicotinic cholinergic receptors (<xref rid="B72" ref-type="bibr">Liu and Simon, 1997</xref>), thus other mechanisms might contribute to this effect as well. Since TRPV1Rs also mediate the perception of spiciness, it may be expected that receptor stimulation by systemic administration of cannabidiol result in such subjective perceptions, given that this mechanism is relevant in humans at the dosage used. Yet, this side effect has not been reported or observed in clinical trials so far (e.g., <xref rid="B68" ref-type="bibr">Leweke et al., 2000</xref>, <xref rid="B67" ref-type="bibr">2012</xref>). To date, evidence for a role of TRPV1R activation in schizophrenia is lacking, but TRPV1Rs may be indirectly involved in schizophrenia via its influence on dopaminergic (<xref rid="B108" ref-type="bibr">Tzavara et al., 2006</xref>) and glutamatergic neurotransmission (<xref rid="B32" ref-type="bibr">Fawley et al., 2014</xref>).</p><p>Furthermore, it has been suggested that cannabidiol targets GPR55 and GPR18 receptors, further subtypes of transient receptor potential receptors (TRPV2, TRPM8, TRPA1), &#x003b1;3 glycine receptors, adenosine receptors, &#x003bc; and &#x003b4; opioid receptors, nicotinic acetylcholine receptors, enzymes of the arachidonic acid cascade, ion channels like voltage-gated calcium channels or mitochondrial Na<sup>+</sup>/Ca<sup>2+</sup> exchange, nitric oxide signaling and inflammatory cytokines (<xref rid="B81" ref-type="bibr">McPartland et al., 2014</xref>; <xref rid="B51" ref-type="bibr">Ibeas Bih et al., 2015</xref>). To date, the antipsychotic properties of cannabidiol cannot be directly linked to these possible targets. However, this does not mean that these mechanisms are not relevant for other medical conditions, e.g., epilepsy (<xref rid="B22" ref-type="bibr">Devinsky et al., 2014</xref>).</p></sec><sec><title>Conclusion</title><p>The antipsychotic potential of cannabidiol has been investigated in various behavioral paradigms and different animal models of aspects of schizophrenia. Although the results were partially inconsistent, they indicate that cannabidiol treatment ameliorates impairments of PPI, social interaction behavior and cognition in rodents and rhesus monkeys. In addition, individual treatment attempts as well as one randomized, double-blind clinical study, demonstrated the antipsychotic potential of cannabidiol and its superior side effect profile compared to conventional antipsychotics. In addition, a recently conducted clinical trial investigating cannabidiol as an add-on medication showed promising results, although these have not yet been published in a peer reviewed process. Obviously more clinical trials are needed to substantiate the current findings, and in particular to investigate long-term efficacy and safety in larger cohorts.</p><p>However, cannabidiol seems to represent a mechanistically different and less side-effect prone antipsychotic compound for the treatment of schizophrenia, even though the underlying pharmacological mechanisms are still under debate. Nevertheless, the association between increased anandamide levels and reduced psychotic symptoms in schizophrenic patients treated with cannabidiol, points to a potentially new antipsychotic mechanism of action involving anandamide.</p></sec><sec><title>Author Contributions</title><p>CR, JKM, BL, and FML performed the review of the literature and CR and FML drafted the manuscript with input from JKM and BL.</p></sec><sec><title>Conflict of Interest Statement</title><p>FML is a shareholder of curantis UG (ltd.). The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>R.</given-names></name></person-group> (<year>1942</year>). <article-title>Marihuana: harvey lecture.</article-title>
<source><italic>Bull. N. Y. Acad. Med.</italic></source>
<volume>18</volume>
<fpage>705</fpage>&#x02013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">19312292</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>R.</given-names></name><name><surname>Baker</surname><given-names>B. R.</given-names></name></person-group> (<year>1940</year>). <article-title>Structure of cannabidiol. VII. A method of synthesis of a tetrahydrocannabinol which possesses marihuana activity.</article-title>
<source><italic>J. Am. Chem. Soc.</italic></source>
<volume>62</volume>
<fpage>2405</fpage>&#x02013;<lpage>2408</lpage>. <pub-id pub-id-type="doi">10.1021/ja01866a041</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>R.</given-names></name><name><surname>Hunt</surname><given-names>M.</given-names></name><name><surname>Clark</surname><given-names>J. H.</given-names></name></person-group> (<year>1940a</year>). <article-title>Structure of cannabidiol, a product isolated from the marihuana extract of minnesota wild hemp. I.</article-title>
<source><italic>J. Am. Chem. Soc.</italic></source>
<volume>62</volume>
<fpage>196</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1021/ja01858a058</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>R.</given-names></name><name><surname>Loewe</surname><given-names>S.</given-names></name><name><surname>Pease</surname><given-names>D. C.</given-names></name><name><surname>Cain</surname><given-names>C. K.</given-names></name><name><surname>Wearn</surname><given-names>R. B.</given-names></name><name><surname>Baker</surname><given-names>R. B.</given-names></name><etal/></person-group> (<year>1940b</year>). <article-title>Structure of cannabidiol. VIII. Position of the double bonds in cannabidiol. Marihuana activity of tetrahydrocannabinols.</article-title>
<source><italic>J. Am. Chem. Soc.</italic></source>
<volume>62</volume>
<fpage>2566</fpage>&#x02013;<lpage>2567</lpage>. <pub-id pub-id-type="doi">10.1021/ja01866a510</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>R.</given-names></name><name><surname>Wolff</surname><given-names>H.</given-names></name><name><surname>Cain</surname><given-names>C. K.</given-names></name><name><surname>Clark</surname><given-names>J. H.</given-names></name></person-group> (<year>1940c</year>). <article-title>Structure of cannabidiol. V. Position of the alicyclic double bonds.</article-title>
<source><italic>J. Am. Chem. Soc.</italic></source>
<volume>62</volume>
<fpage>2215</fpage>&#x02013;<lpage>2219</lpage>. <pub-id pub-id-type="doi">10.1021/ja01865a085</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allentuck</surname><given-names>S.</given-names></name><name><surname>Bowman</surname><given-names>K. M.</given-names></name></person-group> (<year>1942</year>). <article-title>The psychiatric aspects of marihuana intoxication.</article-title>
<source><italic>Am. J. Psychiatry</italic></source>
<volume>99</volume>
<fpage>248</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.99.2.248</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>V.</given-names></name><name><surname>Levin</surname><given-names>R.</given-names></name><name><surname>Peres</surname><given-names>F. F.</given-names></name><name><surname>Niigaki</surname><given-names>S. T.</given-names></name><name><surname>Calzavara</surname><given-names>M. B.</given-names></name><name><surname>Zuardi</surname><given-names>A. W.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test.</article-title>
<source><italic>Prog. Neuropsychopharmacol. Biol. Psychiatry</italic></source>
<volume>41</volume>
<fpage>30</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.10.024</pub-id><pub-id pub-id-type="pmid">23127569</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>V.</given-names></name><name><surname>Peres</surname><given-names>F. F.</given-names></name><name><surname>Levin</surname><given-names>R.</given-names></name><name><surname>Suiama</surname><given-names>M. A.</given-names></name><name><surname>Calzavara</surname><given-names>M. B.</given-names></name><name><surname>Zuardi</surname><given-names>A. W.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain.</article-title>
<source><italic>Schizophr. Res.</italic></source>
<volume>153</volume>
<fpage>150</fpage>&#x02013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2014.01.039</pub-id><pub-id pub-id-type="pmid">24556469</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arseneault</surname><given-names>L.</given-names></name><name><surname>Cannon</surname><given-names>M.</given-names></name><name><surname>Poulton</surname><given-names>R.</given-names></name><name><surname>Murray</surname><given-names>R.</given-names></name><name><surname>Caspi</surname><given-names>A.</given-names></name><name><surname>Moffitt</surname><given-names>T. E.</given-names></name></person-group> (<year>2002</year>). <article-title>Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.</article-title>
<source><italic>BMJ</italic></source>
<volume>325</volume>
<fpage>1212</fpage>&#x02013;<lpage>1213</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.325.7374.1212</pub-id><pub-id pub-id-type="pmid">12446537</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>S.</given-names></name><name><surname>Fusar-Poli</surname><given-names>P.</given-names></name><name><surname>Borgwardt</surname><given-names>S.</given-names></name><name><surname>Martin-Santos</surname><given-names>R.</given-names></name><name><surname>Nosarti</surname><given-names>C.</given-names></name><name><surname>O&#x02019;carroll</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of <italic>Cannabis sativa</italic> on learning and psychosis.</article-title>
<source><italic>Arch. Gen. Psychiatry</italic></source>
<volume>66</volume>
<fpage>442</fpage>&#x02013;<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.17</pub-id><pub-id pub-id-type="pmid">19349314</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bisogno</surname><given-names>T.</given-names></name><name><surname>Hanus</surname><given-names>L.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Tchilibon</surname><given-names>S.</given-names></name><name><surname>Ponde</surname><given-names>D. E.</given-names></name><name><surname>Brandi</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>134</volume>
<fpage>845</fpage>&#x02013;<lpage>852</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0704327</pub-id><pub-id pub-id-type="pmid">11606325</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breivogel</surname><given-names>C. S.</given-names></name><name><surname>Griffin</surname><given-names>G.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Martin</surname><given-names>B. R.</given-names></name></person-group> (<year>2001</year>). <article-title>Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.</article-title>
<source><italic>Mol. Pharmacol.</italic></source>
<volume>60</volume>
<fpage>155</fpage>&#x02013;<lpage>163</lpage>.<pub-id pub-id-type="pmid">11408610</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>A. S.</given-names></name></person-group> (<year>2011</year>). <article-title>The environment and susceptibility to schizophrenia.</article-title>
<source><italic>Prog. Neurobiol.</italic></source>
<volume>93</volume>
<fpage>23</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2010.09.003</pub-id><pub-id pub-id-type="pmid">20955757</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calzavara</surname><given-names>M. B.</given-names></name><name><surname>Levin</surname><given-names>R.</given-names></name><name><surname>Medrano</surname><given-names>W. A.</given-names></name><name><surname>Almeida</surname><given-names>V.</given-names></name><name><surname>Sampaio</surname><given-names>A. P.</given-names></name><name><surname>Barone</surname><given-names>L. C.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats.</article-title>
<source><italic>Behav. Brain Res.</italic></source>
<volume>225</volume>
<fpage>15</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2011.06.026</pub-id><pub-id pub-id-type="pmid">21741413</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calzavara</surname><given-names>M. B.</given-names></name><name><surname>Medrano</surname><given-names>W. A.</given-names></name><name><surname>Levin</surname><given-names>R.</given-names></name><name><surname>Kameda</surname><given-names>S. R.</given-names></name><name><surname>Andersen</surname><given-names>M. L.</given-names></name><name><surname>Tufik</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?</article-title>
<source><italic>Schizophr. Bull.</italic></source>
<volume>35</volume>
<fpage>748</fpage>&#x02013;<lpage>759</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbn006</pub-id><pub-id pub-id-type="pmid">18281713</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>M.</given-names></name><name><surname>Jones</surname><given-names>P.</given-names></name></person-group> (<year>1996</year>). <article-title>Schizophrenia.</article-title>
<source><italic>J. Neurol. Neurosurg. Psychiatry</italic></source>
<volume>60</volume>
<fpage>604</fpage>&#x02013;<lpage>613</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.60.6.604</pub-id><pub-id pub-id-type="pmid">8648325</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corfas</surname><given-names>G.</given-names></name><name><surname>Roy</surname><given-names>K.</given-names></name><name><surname>Buxbaum</surname><given-names>J. D.</given-names></name></person-group> (<year>2004</year>). <article-title>Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia.</article-title>
<source><italic>Nat. Neurosci.</italic></source>
<volume>7</volume>
<fpage>575</fpage>&#x02013;<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1038/nn1258</pub-id><pub-id pub-id-type="pmid">15162166</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><name><surname>Ligresti</surname><given-names>A.</given-names></name><name><surname>Moriello</surname><given-names>A. S.</given-names></name><name><surname>Allara</surname><given-names>M.</given-names></name><name><surname>Bisogno</surname><given-names>T.</given-names></name><name><surname>Petrosino</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>163</volume>
<fpage>1479</fpage>&#x02013;<lpage>1494</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01166.x</pub-id><pub-id pub-id-type="pmid">21175579</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deiana</surname><given-names>S.</given-names></name><name><surname>Watanabe</surname><given-names>A.</given-names></name><name><surname>Yamasaki</surname><given-names>Y.</given-names></name><name><surname>Amada</surname><given-names>N.</given-names></name><name><surname>Kikuchi</surname><given-names>T.</given-names></name><name><surname>Stott</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol.</article-title>
<source><italic>Behav. Pharmacol.</italic></source>
<volume>26</volume>
<fpage>748</fpage>&#x02013;<lpage>765</lpage>. <pub-id pub-id-type="doi">10.1097/fbp.0000000000000178</pub-id><pub-id pub-id-type="pmid">26287433</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devane</surname><given-names>W. A.</given-names></name><name><surname>Dysarz</surname><given-names>F. A.</given-names></name><name><surname>Johnson</surname><given-names>M. R.</given-names></name><name><surname>Melvin</surname><given-names>L. S.</given-names></name><name><surname>Howlett</surname><given-names>A. C.</given-names></name></person-group> (<year>1988</year>). <article-title>Determination and characterization of a cannabinoid receptor in rat brain.</article-title>
<source><italic>Mol. Pharmacol.</italic></source>
<volume>34</volume>
<fpage>605</fpage>&#x02013;<lpage>613</lpage>.<pub-id pub-id-type="pmid">2848184</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devane</surname><given-names>W. A.</given-names></name><name><surname>Hanus</surname><given-names>L.</given-names></name><name><surname>Breuer</surname><given-names>A.</given-names></name><name><surname>Pertwee</surname><given-names>R. G.</given-names></name><name><surname>Stevenson</surname><given-names>L. A.</given-names></name><name><surname>Griffin</surname><given-names>G.</given-names></name><etal/></person-group> (<year>1992</year>). <article-title>Isolation and structure of a brain constituent that binds to the cannabinoid receptor.</article-title>
<source><italic>Science</italic></source>
<volume>258</volume>
<fpage>1946</fpage>&#x02013;<lpage>1949</lpage>. <pub-id pub-id-type="doi">10.1126/science.1470919</pub-id><pub-id pub-id-type="pmid">1470919</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname><given-names>O.</given-names></name><name><surname>Cilio</surname><given-names>M. R.</given-names></name><name><surname>Cross</surname><given-names>H.</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J.</given-names></name><name><surname>French</surname><given-names>J.</given-names></name><name><surname>Hill</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.</article-title>
<source><italic>Epilepsia</italic></source>
<volume>55</volume>
<fpage>791</fpage>&#x02013;<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12631</pub-id><pub-id pub-id-type="pmid">24854329</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Forti</surname><given-names>M.</given-names></name><name><surname>Morgan</surname><given-names>C.</given-names></name><name><surname>Dazzan</surname><given-names>P.</given-names></name><name><surname>Pariante</surname><given-names>C.</given-names></name><name><surname>Mondelli</surname><given-names>V.</given-names></name><name><surname>Marques</surname><given-names>T. R.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>High-potency cannabis and the risk of psychosis.</article-title>
<source><italic>Br. J. Psychiatry</italic></source>
<volume>195</volume>
<fpage>488</fpage>&#x02013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.bp.109.064220</pub-id><pub-id pub-id-type="pmid">19949195</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Forti</surname><given-names>M.</given-names></name><name><surname>Sallis</surname><given-names>H.</given-names></name><name><surname>Allegri</surname><given-names>F.</given-names></name><name><surname>Trotta</surname><given-names>A.</given-names></name><name><surname>Ferraro</surname><given-names>L.</given-names></name><name><surname>Stilo</surname><given-names>S. A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.</article-title>
<source><italic>Schizophr. Bull.</italic></source>
<volume>40</volume>
<fpage>1509</fpage>&#x02013;<lpage>1517</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbt181</pub-id><pub-id pub-id-type="pmid">24345517</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Docherty</surname><given-names>R. J.</given-names></name><name><surname>Yeats</surname><given-names>J. C.</given-names></name><name><surname>Piper</surname><given-names>A. S.</given-names></name></person-group> (<year>1997</year>). <article-title>Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>121</volume>
<fpage>1461</fpage>&#x02013;<lpage>1467</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0701272</pub-id><pub-id pub-id-type="pmid">9257928</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Souza</surname><given-names>D. C.</given-names></name><name><surname>Abi-Saab</surname><given-names>W. M.</given-names></name><name><surname>Madonick</surname><given-names>S.</given-names></name><name><surname>Forselius-Bielen</surname><given-names>K.</given-names></name><name><surname>Doersch</surname><given-names>A.</given-names></name><name><surname>Braley</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>57</volume>
<fpage>594</fpage>&#x02013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2004.12.006</pub-id><pub-id pub-id-type="pmid">15780846</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Souza</surname><given-names>D. C.</given-names></name><name><surname>Perry</surname><given-names>E.</given-names></name><name><surname>Macdougall</surname><given-names>L.</given-names></name><name><surname>Ammerman</surname><given-names>Y.</given-names></name><name><surname>Cooper</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>Y. T.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.</article-title>
<source><italic>Neuropsychopharmacology</italic></source>
<volume>29</volume>
<fpage>1558</fpage>&#x02013;<lpage>1572</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300496</pub-id><pub-id pub-id-type="pmid">15173844</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmes</surname><given-names>M. W.</given-names></name><name><surname>Kaczocha</surname><given-names>M.</given-names></name><name><surname>Berger</surname><given-names>W. T.</given-names></name><name><surname>Leung</surname><given-names>K.</given-names></name><name><surname>Ralph</surname><given-names>B. P.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Fatty acid-binding proteins (FABPs) are intracellular carriers for Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD).</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>290</volume>
<fpage>8711</fpage>&#x02013;<lpage>8721</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.618447</pub-id><pub-id pub-id-type="pmid">25666611</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emrich</surname><given-names>H. M.</given-names></name><name><surname>Leweke</surname><given-names>F. M.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name></person-group> (<year>1997</year>). <article-title>Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.</article-title>
<source><italic>Pharmacol. Biochem. Behav.</italic></source>
<volume>56</volume>
<fpage>803</fpage>&#x02013;<lpage>807</lpage>. <pub-id pub-id-type="doi">10.1016/S0091-3057(96)00426-1</pub-id><pub-id pub-id-type="pmid">9130308</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadda</surname><given-names>P.</given-names></name><name><surname>Robinson</surname><given-names>L.</given-names></name><name><surname>Fratta</surname><given-names>W.</given-names></name><name><surname>Pertwee</surname><given-names>R. G.</given-names></name><name><surname>Riedel</surname><given-names>G.</given-names></name></person-group> (<year>2004</year>). <article-title>Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats.</article-title>
<source><italic>Neuropharmacology</italic></source>
<volume>47</volume>
<fpage>1170</fpage>&#x02013;<lpage>1179</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.08.009</pub-id><pub-id pub-id-type="pmid">15567426</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadda</surname><given-names>P.</given-names></name><name><surname>Robinson</surname><given-names>L.</given-names></name><name><surname>Fratta</surname><given-names>W.</given-names></name><name><surname>Pertwee</surname><given-names>R. G.</given-names></name><name><surname>Riedel</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis extracts.</article-title>
<source><italic>Behav. Brain Res.</italic></source>
<volume>168</volume>
<fpage>307</fpage>&#x02013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2005.11.022</pub-id><pub-id pub-id-type="pmid">16406104</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fawley</surname><given-names>J. A.</given-names></name><name><surname>Hofmann</surname><given-names>M. E.</given-names></name><name><surname>Andresen</surname><given-names>M. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Cannabinoid 1 and transient receptor potential vanilloid 1 receptors discretely modulate evoked glutamate separately from spontaneous glutamate transmission.</article-title>
<source><italic>J. Neurosci.</italic></source>
<volume>34</volume>
<fpage>8324</fpage>&#x02013;<lpage>8332</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.0315-14.2014</pub-id><pub-id pub-id-type="pmid">24920635</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>R.</given-names></name></person-group> (<year>2003</year>). <article-title>Schizophrenia.</article-title>
<source><italic>N. Engl. J. Med.</italic></source>
<volume>349</volume>
<fpage>1738</fpage>&#x02013;<lpage>1749</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra035458</pub-id><pub-id pub-id-type="pmid">14585943</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Bottegoni</surname><given-names>G.</given-names></name><name><surname>Sasso</surname><given-names>O.</given-names></name><name><surname>Bertorelli</surname><given-names>R.</given-names></name><name><surname>Rocchia</surname><given-names>W.</given-names></name><name><surname>Masetti</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A catalytically silent FAAH-1 variant drives anandamide transport in neurons.</article-title>
<source><italic>Nat. Neurosci.</italic></source>
<volume>15</volume>
<fpage>64</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2986</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusar-Poli</surname><given-names>P.</given-names></name><name><surname>Crippa</surname><given-names>J. A.</given-names></name><name><surname>Bhattacharyya</surname><given-names>S.</given-names></name><name><surname>Borgwardt</surname><given-names>S. J.</given-names></name><name><surname>Allen</surname><given-names>P.</given-names></name><name><surname>Martin-Santos</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Distinct Effects of {Delta}9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing.</article-title>
<source><italic>Arch. Gen. Psychiatry</italic></source>
<volume>66</volume>
<fpage>95</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2008.519</pub-id><pub-id pub-id-type="pmid">19124693</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gage</surname><given-names>S. H.</given-names></name><name><surname>Hickman</surname><given-names>M.</given-names></name><name><surname>Zammit</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Association between cannabis and psychosis: epidemiologic evidence.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>79</volume>
<fpage>549</fpage>&#x02013;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.08.001</pub-id><pub-id pub-id-type="pmid">26386480</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaoni</surname><given-names>Y.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group> (<year>1964</year>). <article-title>Isolation structure + partial synthesis of active constituent of hashish.</article-title>
<source><italic>J. Am. Chem. Soc.</italic></source>
<volume>86</volume>
<fpage>1646</fpage>&#x02013;<lpage>1647</lpage>. <pub-id pub-id-type="doi">10.1021/ja01062a046</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>F. V.</given-names></name><name><surname>Del Bel</surname><given-names>E. A.</given-names></name><name><surname>Guimaraes</surname><given-names>F. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice.</article-title>
<source><italic>Prog. Neuropsychopharmacol. Biol. Psychiatry</italic></source>
<volume>46</volume>
<fpage>43</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.06.005</pub-id><pub-id pub-id-type="pmid">23791616</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>F. V.</given-names></name><name><surname>Issy</surname><given-names>A. C.</given-names></name><name><surname>Ferreira</surname><given-names>F. R.</given-names></name><name><surname>Viveros</surname><given-names>M. P.</given-names></name><name><surname>Del Bel</surname><given-names>E. A.</given-names></name><name><surname>Guimaraes</surname><given-names>F. S.</given-names></name></person-group> (<year>2015a</year>). <article-title>Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice.</article-title>
<source><italic>Int. J. Neuropsychopharmacol.</italic></source>
<volume>18</volume>:<issue>yu041</issue>
<pub-id pub-id-type="doi">10.1093/ijnp/pyu041</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>F. V.</given-names></name><name><surname>Llorente</surname><given-names>R.</given-names></name><name><surname>Del Bel</surname><given-names>E. A.</given-names></name><name><surname>Viveros</surname><given-names>M. P.</given-names></name><name><surname>Lopez-Gallardo</surname><given-names>M.</given-names></name><name><surname>Guimaraes</surname><given-names>F. S.</given-names></name></person-group> (<year>2015b</year>). <article-title>Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.</article-title>
<source><italic>Schizophr. Res.</italic></source>
<volume>164</volume>
<fpage>155</fpage>&#x02013;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2015.01.015</pub-id><pub-id pub-id-type="pmid">25680767</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granja</surname><given-names>A. G.</given-names></name><name><surname>Carrillo-Salinas</surname><given-names>F.</given-names></name><name><surname>Pagani</surname><given-names>A.</given-names></name><name><surname>Gomez-Canas</surname><given-names>M.</given-names></name><name><surname>Negri</surname><given-names>R.</given-names></name><name><surname>Navarrete</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.</article-title>
<source><italic>J. Neuroimmune Pharmacol.</italic></source>
<volume>7</volume>
<fpage>1002</fpage>&#x02013;<lpage>1016</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-012-9399-3</pub-id><pub-id pub-id-type="pmid">22971837</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gururajan</surname><given-names>A.</given-names></name><name><surname>Taylor</surname><given-names>D. A.</given-names></name><name><surname>Malone</surname><given-names>D. T.</given-names></name></person-group> (<year>2011</year>). <article-title>Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.</article-title>
<source><italic>Behav. Brain Res.</italic></source>
<volume>222</volume>
<fpage>299</fpage>&#x02013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2011.03.053</pub-id><pub-id pub-id-type="pmid">21458498</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gururajan</surname><given-names>A.</given-names></name><name><surname>Taylor</surname><given-names>D. A.</given-names></name><name><surname>Malone</surname><given-names>D. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats.</article-title>
<source><italic>J. Psychopharmacol.</italic></source>
<volume>26</volume>
<fpage>1317</fpage>&#x02013;<lpage>1332</lpage>. <pub-id pub-id-type="doi">10.1177/0269881112441865</pub-id><pub-id pub-id-type="pmid">22495620</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><collab>GW Pharmaceuticals plc</collab> (<year>2015</year>). <source><italic>GW Pharmaceuticals Announces Positive Proof of Concept Data in Schizophrenia.</italic></source> Available at: <ext-link ext-link-type="uri" xlink:href="http://globenewswire.com/news-release/2015/09/15/768364/10149367/en/GW-Pharmaceuticals-Announces-Positive-Proof-of-Concept-Data-in-Schizophrenia.html?f=22\&#x00026;fvtc=3\&#x00026;fvtv=4000">http://globenewswire.com/news-release/2015/09/15/768364/10149367/en/GW-Pharmaceuticals-Announces-Positive-Proof-of-Concept-Data-in-Schizophrenia.html?f=22\&#x00026;fvtc=3\&#x00026;fvtv=4000</ext-link> [accessed June <volume>28</volume>
<issue>2016</issue>].</mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallak</surname><given-names>J. E.</given-names></name><name><surname>Machado-De-Sousa</surname><given-names>J. P.</given-names></name><name><surname>Crippa</surname><given-names>J. A.</given-names></name><name><surname>Sanches</surname><given-names>R. F.</given-names></name><name><surname>Trzesniak</surname><given-names>C.</given-names></name><name><surname>Chaves</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD).</article-title>
<source><italic>Rev. Bras. Psiquiatr.</italic></source>
<volume>32</volume>
<fpage>56</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1590/S1516-44462010000100011</pub-id><pub-id pub-id-type="pmid">20339735</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>E.</given-names></name><name><surname>Healey</surname><given-names>K.</given-names></name><name><surname>Wolf</surname><given-names>D.</given-names></name><name><surname>Kohler</surname><given-names>C.</given-names></name></person-group> (<year>2010</year>). <article-title>Assessment of pharmacotherapy for negative symptoms of schizophrenia.</article-title>
<source><italic>Curr. Psychiatry Rep.</italic></source>
<volume>12</volume>
<fpage>563</fpage>&#x02013;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1007/s11920-010-0148-0</pub-id><pub-id pub-id-type="pmid">20821286</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>E.</given-names></name><name><surname>Tsang</surname><given-names>T. M.</given-names></name><name><surname>Huang</surname><given-names>J. T.</given-names></name><name><surname>Leweke</surname><given-names>F. M.</given-names></name><name><surname>Koethe</surname><given-names>D.</given-names></name><name><surname>Gerth</surname><given-names>C. W.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia.</article-title>
<source><italic>PLoS Med.</italic></source>
<volume>3</volume>:<issue>e327</issue>
<pub-id pub-id-type="doi">10.1371/journal.pmed.0030327</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>M. E.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>Evans</surname><given-names>G. C.</given-names></name><name><surname>Bucci</surname><given-names>D. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Voluntary physical exercise alters attentional orienting and social behavior in a rat model of attention-deficit/hyperactivity disorder.</article-title>
<source><italic>Behav. Neurosci.</italic></source>
<volume>123</volume>
<fpage>599</fpage>&#x02013;<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1037/a0015632</pub-id><pub-id pub-id-type="pmid">19485566</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>A. C.</given-names></name></person-group> (<year>1984</year>). <article-title>Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds.</article-title>
<source><italic>Life Sci.</italic></source>
<volume>35</volume>
<fpage>1803</fpage>&#x02013;<lpage>1810</lpage>. <pub-id pub-id-type="doi">10.1016/0024-3205(84)90278-9</pub-id><pub-id pub-id-type="pmid">6090851</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iannotti</surname><given-names>F. A.</given-names></name><name><surname>Hill</surname><given-names>C. L.</given-names></name><name><surname>Leo</surname><given-names>A.</given-names></name><name><surname>Alhusaini</surname><given-names>A.</given-names></name><name><surname>Soubrane</surname><given-names>C.</given-names></name><name><surname>Mazzarella</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.</article-title>
<source><italic>ACS Chem. Neurosci.</italic></source>
<volume>5</volume>
<fpage>1131</fpage>&#x02013;<lpage>1141</lpage>. <pub-id pub-id-type="doi">10.1021/cn5000524</pub-id><pub-id pub-id-type="pmid">25029033</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibeas Bih</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Nunn</surname><given-names>A. V.</given-names></name><name><surname>Bazelot</surname><given-names>M.</given-names></name><name><surname>Dallas</surname><given-names>M.</given-names></name><name><surname>Whalley</surname><given-names>B. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Molecular targets of cannabidiol in neurological disorders.</article-title>
<source><italic>Neurotherapeutics</italic></source>
<volume>12</volume>
<fpage>699</fpage>&#x02013;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-015-0377-3</pub-id><pub-id pub-id-type="pmid">26264914</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>N. A.</given-names></name><name><surname>Hill</surname><given-names>A. J.</given-names></name><name><surname>Smith</surname><given-names>I.</given-names></name><name><surname>Bevan</surname><given-names>S. A.</given-names></name><name><surname>Williams</surname><given-names>C. M.</given-names></name><name><surname>Whalley</surname><given-names>B. J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.</article-title>
<source><italic>J. Pharmacol. Exp. Ther.</italic></source>
<volume>332</volume>
<fpage>569</fpage>&#x02013;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.109.159145</pub-id><pub-id pub-id-type="pmid">19906779</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>P. G.</given-names></name><name><surname>Falvello</surname><given-names>L.</given-names></name><name><surname>Kennard</surname><given-names>O.</given-names></name><name><surname>Sheldrick</surname><given-names>G. M.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group> (<year>1977</year>). <article-title>Cannabidiol.</article-title>
<source><italic>Acta Crystallogr. B</italic></source>
<volume>33</volume>
<fpage>3211</fpage>&#x02013;<lpage>3214</lpage>. <pub-id pub-id-type="doi">10.1107/S0567740877010577</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczocha</surname><given-names>M.</given-names></name><name><surname>Glaser</surname><given-names>S. T.</given-names></name><name><surname>Deutsch</surname><given-names>D. G.</given-names></name></person-group> (<year>2009</year>). <article-title>Identification of intracellular carriers for the endocannabinoid anandamide.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>106</volume>
<fpage>6375</fpage>&#x02013;<lpage>6380</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0901515106</pub-id><pub-id pub-id-type="pmid">19307565</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczocha</surname><given-names>M.</given-names></name><name><surname>Vivieca</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Glaser</surname><given-names>S. T.</given-names></name><name><surname>Deutsch</surname><given-names>D. G.</given-names></name></person-group> (<year>2012</year>). <article-title>Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>287</volume>
<fpage>3415</fpage>&#x02013;<lpage>3424</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.304907</pub-id><pub-id pub-id-type="pmid">22170058</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>R. S.</given-names></name><name><surname>Sommer</surname><given-names>I. E.</given-names></name><name><surname>Murray</surname><given-names>R. M.</given-names></name><name><surname>Meyer-Lindenberg</surname><given-names>A.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name><name><surname>Cannon</surname><given-names>T. D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Schizophrenia.</article-title>
<source><italic>Nat. Rev. Dis. Primers</italic></source>
<volume>1</volume>:<issue>15067</issue>
<pub-id pub-id-type="doi">10.1038/nrdp.2015.67</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J. S.</given-names></name><name><surname>Kornhuber</surname><given-names>H. H.</given-names></name><name><surname>Schmid-Burgk</surname><given-names>W.</given-names></name><name><surname>Holzmuller</surname><given-names>B.</given-names></name></person-group> (<year>1980</year>). <article-title>Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.</article-title>
<source><italic>Neurosci. Lett.</italic></source>
<volume>20</volume>
<fpage>379</fpage>&#x02013;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(80)90178-0</pub-id><pub-id pub-id-type="pmid">6108541</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koethe</surname><given-names>D.</given-names></name><name><surname>Gerth</surname><given-names>C. W.</given-names></name><name><surname>Neatby</surname><given-names>M. A.</given-names></name><name><surname>Haensel</surname><given-names>A.</given-names></name><name><surname>Thies</surname><given-names>M.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness.</article-title>
<source><italic>Schizophr. Res.</italic></source>
<volume>88</volume>
<fpage>142</fpage>&#x02013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2006.07.023</pub-id><pub-id pub-id-type="pmid">17005373</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koethe</surname><given-names>D.</given-names></name><name><surname>Hoyer</surname><given-names>C.</given-names></name><name><surname>Leweke</surname><given-names>F. M.</given-names></name></person-group> (<year>2009</year>). <article-title>The endocannabinoid system as a target for modelling psychosis.</article-title>
<source><italic>Psychopharmacology (Berl.)</italic></source>
<volume>206</volume>
<fpage>551</fpage>&#x02013;<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-009-1591-7</pub-id><pub-id pub-id-type="pmid">19529920</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laprairie</surname><given-names>R. B.</given-names></name><name><surname>Bagher</surname><given-names>A. M.</given-names></name><name><surname>Kelly</surname><given-names>M. E.</given-names></name><name><surname>Denovan-Wright</surname><given-names>E. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>172</volume>
<fpage>4790</fpage>&#x02013;<lpage>4805</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13250</pub-id><pub-id pub-id-type="pmid">26218440</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laprairie</surname><given-names>R. B.</given-names></name><name><surname>Bagher</surname><given-names>A. M.</given-names></name><name><surname>Kelly</surname><given-names>M. E.</given-names></name><name><surname>Dupre</surname><given-names>D. J.</given-names></name><name><surname>Denovan-Wright</surname><given-names>E. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>289</volume>
<fpage>24845</fpage>&#x02013;<lpage>24862</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.557025</pub-id><pub-id pub-id-type="pmid">25037227</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leucht</surname><given-names>S.</given-names></name><name><surname>Pitschel-Walz</surname><given-names>G.</given-names></name><name><surname>Engel</surname><given-names>R. R.</given-names></name><name><surname>Kissling</surname><given-names>W.</given-names></name></person-group> (<year>2002</year>). <article-title>Amisulpride, an unusual &#x0201c;atypical&#x0201d; antipsychotic: a meta-analysis of randomized controlled trials.</article-title>
<source><italic>Am. J. Psychiatry</italic></source>
<volume>159</volume>
<fpage>180</fpage>&#x02013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.159.2.180</pub-id><pub-id pub-id-type="pmid">11823257</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>R.</given-names></name><name><surname>Calzavara</surname><given-names>M. B.</given-names></name><name><surname>Santos</surname><given-names>C. M.</given-names></name><name><surname>Medrano</surname><given-names>W. A.</given-names></name><name><surname>Niigaki</surname><given-names>S. T.</given-names></name><name><surname>Abilio</surname><given-names>V. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Spontaneously hypertensive rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine.</article-title>
<source><italic>Prog. Neuropsychopharmacol. Biol. Psychiatry</italic></source>
<volume>35</volume>
<fpage>1748</fpage>&#x02013;<lpage>1752</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2011.06.003</pub-id><pub-id pub-id-type="pmid">21693159</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levin</surname><given-names>R.</given-names></name><name><surname>Peres</surname><given-names>F. F.</given-names></name><name><surname>Almeida</surname><given-names>V.</given-names></name><name><surname>Calzavara</surname><given-names>M. B.</given-names></name><name><surname>Zuardi</surname><given-names>A. W.</given-names></name><name><surname>Hallak</surname><given-names>J. E.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain.</article-title>
<source><italic>Front. Pharmacol.</italic></source>
<volume>5</volume>:<issue>10</issue>
<pub-id pub-id-type="doi">10.3389/fphar.2014.00010</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leweke</surname><given-names>F. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Anandamide dysfunction in prodromal and established psychosis.</article-title>
<source><italic>Curr. Pharm. Des.</italic></source>
<volume>18</volume>
<fpage>5188</fpage>&#x02013;<lpage>5193</lpage>. <pub-id pub-id-type="doi">10.2174/138161212802884843</pub-id><pub-id pub-id-type="pmid">22716147</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leweke</surname><given-names>F. M.</given-names></name><name><surname>Mueller</surname><given-names>J. K.</given-names></name><name><surname>Lange</surname><given-names>B.</given-names></name><name><surname>Rohleder</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Therapeutic potential of cannabinoids in psychosis.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>79</volume>
<fpage>604</fpage>&#x02013;<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.11.018</pub-id><pub-id pub-id-type="pmid">26852073</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leweke</surname><given-names>F. M.</given-names></name><name><surname>Piomelli</surname><given-names>D.</given-names></name><name><surname>Pahlisch</surname><given-names>F.</given-names></name><name><surname>Muhl</surname><given-names>D.</given-names></name><name><surname>Gerth</surname><given-names>C. W.</given-names></name><name><surname>Hoyer</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.</article-title>
<source><italic>Transl. Psychiatry</italic></source>
<volume>2</volume>:<issue>e94</issue>
<pub-id pub-id-type="doi">10.1038/tp.2012.15</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leweke</surname><given-names>F. M.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><name><surname>Radwan</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>E.</given-names></name><name><surname>Emrich</surname><given-names>H. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Different effects of nabilone and cannabidiol on binocular depth inversion in man.</article-title>
<source><italic>Pharmacol. Biochem. Behav.</italic></source>
<volume>66</volume>
<fpage>175</fpage>&#x02013;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/S0091-3057(00)00201-X</pub-id><pub-id pub-id-type="pmid">10837858</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leweke</surname><given-names>F. M.</given-names></name><name><surname>Schneider</surname><given-names>U.</given-names></name><name><surname>Thies</surname><given-names>M.</given-names></name><name><surname>M&#x000fc;nte</surname><given-names>T. F.</given-names></name><name><surname>Emrich</surname><given-names>H. M.</given-names></name></person-group> (<year>1999</year>). <article-title>Effects of synthetic &#x00394;9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man.</article-title>
<source><italic>Psychopharmacology</italic></source>
<volume>142</volume>
<fpage>230</fpage>&#x02013;<lpage>235</lpage>. <pub-id pub-id-type="doi">10.1007/s002130050884</pub-id><pub-id pub-id-type="pmid">10208314</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leza</surname><given-names>J. C.</given-names></name><name><surname>Garcia-Bueno</surname><given-names>B.</given-names></name><name><surname>Bioque</surname><given-names>M.</given-names></name><name><surname>Arango</surname><given-names>C.</given-names></name><name><surname>Parellada</surname><given-names>M.</given-names></name><name><surname>Do</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Inflammation in schizophrenia: a question of balance.</article-title>
<source><italic>Neurosci. Biobehav. Rev.</italic></source>
<volume>55</volume>
<fpage>612</fpage>&#x02013;<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.05.014</pub-id><pub-id pub-id-type="pmid">26092265</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligresti</surname><given-names>A.</given-names></name><name><surname>Moriello</surname><given-names>A. S.</given-names></name><name><surname>Starowicz</surname><given-names>K.</given-names></name><name><surname>Matias</surname><given-names>I.</given-names></name><name><surname>Pisanti</surname><given-names>S.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.</article-title>
<source><italic>J. Pharmacol. Exp. Ther.</italic></source>
<volume>318</volume>
<fpage>1375</fpage>&#x02013;<lpage>1387</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.106.105247</pub-id><pub-id pub-id-type="pmid">16728591</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Simon</surname><given-names>S. A.</given-names></name></person-group> (<year>1997</year>). <article-title>Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia.</article-title>
<source><italic>Neurosci. Lett.</italic></source>
<volume>228</volume>
<fpage>29</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3940(97)00358-3</pub-id><pub-id pub-id-type="pmid">9197280</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>L. E.</given-names></name><name><surname>Chesworth</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>X. F.</given-names></name><name><surname>Mcgregor</surname><given-names>I. S.</given-names></name><name><surname>Arnold</surname><given-names>J. C.</given-names></name><name><surname>Karl</surname><given-names>T.</given-names></name></person-group> (<year>2010</year>). <article-title>A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.</article-title>
<source><italic>Int. J. Neuropsychopharmacol.</italic></source>
<volume>13</volume>
<fpage>861</fpage>&#x02013;<lpage>876</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145709990605</pub-id><pub-id pub-id-type="pmid">19785914</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>L. E.</given-names></name><name><surname>Chesworth</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>X. F.</given-names></name><name><surname>Wong</surname><given-names>A.</given-names></name><name><surname>Spiro</surname><given-names>A.</given-names></name><name><surname>Mcgregor</surname><given-names>I. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice.</article-title>
<source><italic>PLoS ONE</italic></source>
<volume>7</volume>:<issue>e34129</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0034129</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>L. E.</given-names></name><name><surname>Malone</surname><given-names>D. T.</given-names></name><name><surname>Taylor</surname><given-names>D. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice.</article-title>
<source><italic>Neuropsychopharmacology</italic></source>
<volume>31</volume>
<fpage>795</fpage>&#x02013;<lpage>803</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300838</pub-id><pub-id pub-id-type="pmid">16052245</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.-C.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>An introduction to the endogenous cannabinoid system.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>79</volume>
<fpage>516</fpage>&#x02013;<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.07.028</pub-id><pub-id pub-id-type="pmid">26698193</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>B.</given-names></name><name><surname>Marsicano</surname><given-names>G.</given-names></name><name><surname>Maldonado</surname><given-names>R.</given-names></name><name><surname>Hillard</surname><given-names>C. J.</given-names></name></person-group> (<year>2015</year>). <article-title>The endocannabinoid system in guarding against fear, anxiety and stress.</article-title>
<source><italic>Nat. Rev. Neurosci.</italic></source>
<volume>16</volume>
<fpage>705</fpage>&#x02013;<lpage>718</lpage>. <pub-id pub-id-type="doi">10.1038/nrn4036</pub-id><pub-id pub-id-type="pmid">26585799</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malone</surname><given-names>D. T.</given-names></name><name><surname>Jongejan</surname><given-names>D.</given-names></name><name><surname>Taylor</surname><given-names>D. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.</article-title>
<source><italic>Pharmacol. Biochem. Behav.</italic></source>
<volume>93</volume>
<fpage>91</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2009.04.010</pub-id><pub-id pub-id-type="pmid">19393686</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>O.</given-names></name><name><surname>Morgan</surname><given-names>C. J.</given-names></name><name><surname>Dhiman</surname><given-names>S. K.</given-names></name><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Parti</surname><given-names>N.</given-names></name><name><surname>Patel</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis.</article-title>
<source><italic>Psychol. Med.</italic></source>
<volume>39</volume>
<fpage>951</fpage>&#x02013;<lpage>956</lpage>. <pub-id pub-id-type="doi">10.1017/s0033291708004741</pub-id><pub-id pub-id-type="pmid">19017430</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>L. A.</given-names></name><name><surname>Lolait</surname><given-names>S. J.</given-names></name><name><surname>Brownstein</surname><given-names>M. J.</given-names></name><name><surname>Young</surname><given-names>A. C.</given-names></name><name><surname>Bonner</surname><given-names>T. I.</given-names></name></person-group> (<year>1990</year>). <article-title>Structure of a cannabinoid receptor and functional expression of the cloned cDNA.</article-title>
<source><italic>Nature</italic></source>
<volume>346</volume>
<fpage>561</fpage>&#x02013;<lpage>564</lpage>. <pub-id pub-id-type="doi">10.1038/346561a0</pub-id><pub-id pub-id-type="pmid">2165569</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McPartland</surname><given-names>J. M.</given-names></name><name><surname>Duncan</surname><given-names>M.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Pertwee</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Are cannabidiol and Delta -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>172</volume>
<fpage>737</fpage>&#x02013;<lpage>753</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12944</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Ben-Shabat</surname><given-names>S.</given-names></name><name><surname>Hanus</surname><given-names>L.</given-names></name><name><surname>Ligumsky</surname><given-names>M.</given-names></name><name><surname>Kaminski</surname><given-names>N. E.</given-names></name><name><surname>Schatz</surname><given-names>A. R.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.</article-title>
<source><italic>Biochem. Pharmacol.</italic></source>
<volume>50</volume>
<fpage>83</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(95)00109-D</pub-id><pub-id pub-id-type="pmid">7605349</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Shani</surname><given-names>A.</given-names></name><name><surname>Edery</surname><given-names>H.</given-names></name><name><surname>Grunfeld</surname><given-names>Y.</given-names></name></person-group> (<year>1970</year>). <article-title>Chemical basis of hashish activity.</article-title>
<source><italic>Science</italic></source>
<volume>169</volume>
<fpage>611</fpage>&#x02013;<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1126/science.169.3945.611</pub-id><pub-id pub-id-type="pmid">4987683</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechoulam</surname><given-names>R.</given-names></name><name><surname>Shvo</surname><given-names>Y.</given-names></name></person-group> (<year>1963</year>). <article-title>Hashish&#x02014;I : the structure of cannabidiol.</article-title>
<source><italic>Tetrahedron</italic></source>
<volume>19</volume>
<fpage>2073</fpage>&#x02013;<lpage>2078</lpage>. <pub-id pub-id-type="doi">10.1016/0040-4020(63)85022-x</pub-id><pub-id pub-id-type="pmid">5879214</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>T. H.</given-names></name><name><surname>Zammit</surname><given-names>S.</given-names></name><name><surname>Lingford-Hughes</surname><given-names>A.</given-names></name><name><surname>Barnes</surname><given-names>T. R.</given-names></name><name><surname>Jones</surname><given-names>P. B.</given-names></name><name><surname>Burke</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.</article-title>
<source><italic>Lancet</italic></source>
<volume>370</volume>
<fpage>319</fpage>&#x02013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61162-3</pub-id><pub-id pub-id-type="pmid">17662880</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munro</surname><given-names>S.</given-names></name><name><surname>Thomas</surname><given-names>K. L.</given-names></name><name><surname>Abu-Shaar</surname><given-names>M.</given-names></name></person-group> (<year>1993</year>). <article-title>Molecular characterization of a peripheral receptor for cannabinoids.</article-title>
<source><italic>Nature</italic></source>
<volume>365</volume>
<fpage>61</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1038/365061a0</pub-id><pub-id pub-id-type="pmid">7689702</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newell</surname><given-names>K. A.</given-names></name><name><surname>Karl</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>X. F.</given-names></name></person-group> (<year>2013</year>). <article-title>A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice.</article-title>
<source><italic>Neuroscience</italic></source>
<volume>248</volume>
<fpage>670</fpage>&#x02013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.06.037</pub-id><pub-id pub-id-type="pmid">23811072</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Sullivan</surname><given-names>S. E.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Bennett</surname><given-names>A. J.</given-names></name><name><surname>Randall</surname><given-names>M. D.</given-names></name><name><surname>Kendall</surname><given-names>D. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Time-dependent vascular actions of cannabidiol in the rat aorta.</article-title>
<source><italic>Eur. J. Pharmacol.</italic></source>
<volume>612</volume>
<fpage>61</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2009.03.010</pub-id><pub-id pub-id-type="pmid">19285060</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedrazzi</surname><given-names>J. F.</given-names></name><name><surname>Issy</surname><given-names>A. C.</given-names></name><name><surname>Gomes</surname><given-names>F. V.</given-names></name><name><surname>Guimaraes</surname><given-names>F. S.</given-names></name><name><surname>Del-Bel</surname><given-names>E. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.</article-title>
<source><italic>Psychopharmacology (Berl.)</italic></source>
<volume>232</volume>
<fpage>3057</fpage>&#x02013;<lpage>3065</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-015-3945-7</pub-id><pub-id pub-id-type="pmid">25943166</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pertwee</surname><given-names>R. G.</given-names></name><name><surname>Ross</surname><given-names>R. A.</given-names></name><name><surname>Craib</surname><given-names>S. J.</given-names></name><name><surname>Thomas</surname><given-names>A.</given-names></name></person-group> (<year>2002</year>). <article-title>(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens.</article-title>
<source><italic>Eur. J. Pharmacol.</italic></source>
<volume>456</volume>
<fpage>99</fpage>&#x02013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(02)02624-9</pub-id><pub-id pub-id-type="pmid">12450575</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petitet</surname><given-names>F.</given-names></name><name><surname>Jeantaud</surname><given-names>B.</given-names></name><name><surname>Reibaud</surname><given-names>M.</given-names></name><name><surname>Imperato</surname><given-names>A.</given-names></name><name><surname>Dubroeucq</surname><given-names>M. C.</given-names></name></person-group> (<year>1998</year>). <article-title>Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.</article-title>
<source><italic>Life Sci.</italic></source>
<volume>63</volume>
<fpage>L1</fpage>&#x02013;<lpage>L6</lpage>. <pub-id pub-id-type="doi">10.1016/S0024-3205(98)00238-0</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajasekaran</surname><given-names>A.</given-names></name><name><surname>Venkatasubramanian</surname><given-names>G.</given-names></name><name><surname>Berk</surname><given-names>M.</given-names></name><name><surname>Debnath</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications.</article-title>
<source><italic>Neurosci. Biobehav. Rev.</italic></source>
<volume>48</volume>
<fpage>10</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2014.11.005</pub-id><pub-id pub-id-type="pmid">25446950</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakhshan</surname><given-names>F.</given-names></name><name><surname>Day</surname><given-names>T. A.</given-names></name><name><surname>Blakely</surname><given-names>R. D.</given-names></name><name><surname>Barker</surname><given-names>E. L.</given-names></name></person-group> (<year>2000</year>). <article-title>Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells.</article-title>
<source><italic>J. Pharmacol. Exp. Ther.</italic></source>
<volume>292</volume>
<fpage>960</fpage>&#x02013;<lpage>967</lpage>.<pub-id pub-id-type="pmid">10688610</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>E. M.</given-names></name><name><surname>Bolognini</surname><given-names>D.</given-names></name><name><surname>Limebeer</surname><given-names>C. L.</given-names></name><name><surname>Cascio</surname><given-names>M. G.</given-names></name><name><surname>Anavi-Goffer</surname><given-names>S.</given-names></name><name><surname>Fletcher</surname><given-names>P. J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>165</volume>
<fpage>2620</fpage>&#x02013;<lpage>2634</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01621.x</pub-id><pub-id pub-id-type="pmid">21827451</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohleder</surname><given-names>C.</given-names></name><name><surname>Wiedermann</surname><given-names>D.</given-names></name><name><surname>Neumaier</surname><given-names>B.</given-names></name><name><surname>Drzezga</surname><given-names>A.</given-names></name><name><surname>Timmermann</surname><given-names>L.</given-names></name><name><surname>Graf</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>The functional networks of prepulse inhibition: neuronal connectivity analysis based on FDG-PET in awake and unrestrained rats.</article-title>
<source><italic>Front. Behav. Neurosci.</italic></source>
<volume>10</volume>:<issue>148</issue>
<pub-id pub-id-type="doi">10.3389/fnbeh.2016.00148</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubino</surname><given-names>T.</given-names></name><name><surname>Parolaro</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>The impact of exposure to cannabinoids in adolescence: insights from animal models.</article-title>
<source><italic>Biological Psychiatry</italic></source>
<volume>79</volume>
<fpage>578</fpage>&#x02013;<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.07.024</pub-id><pub-id pub-id-type="pmid">26344755</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>E. B.</given-names></name><name><surname>Burnett</surname><given-names>A.</given-names></name><name><surname>Hall</surname><given-names>B.</given-names></name><name><surname>Parker</surname><given-names>K. K.</given-names></name></person-group> (<year>2005</year>). <article-title>Agonistic properties of cannabidiol at 5-HT1a receptors.</article-title>
<source><italic>Neurochem. Res.</italic></source>
<volume>30</volume>
<fpage>1037</fpage>&#x02013;<lpage>1043</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-005-6978-1</pub-id><pub-id pub-id-type="pmid">16258853</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarcz</surname><given-names>G.</given-names></name><name><surname>Karajgi</surname><given-names>B.</given-names></name><name><surname>Mccarthy</surname><given-names>R.</given-names></name></person-group> (<year>2009</year>). <article-title>Synthetic &#x00394;-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia.</article-title>
<source><italic>J. Clin. Psychopharmacol.</italic></source>
<volume>29</volume>
<fpage>255</fpage>&#x02013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1097/JCP.0b013e3181a6bc3b</pub-id><pub-id pub-id-type="pmid">19440079</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherif</surname><given-names>M.</given-names></name><name><surname>Radhakrishnan</surname><given-names>R.</given-names></name><name><surname>D&#x02019;souza</surname><given-names>D. C.</given-names></name><name><surname>Ranganathan</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Human laboratory studies on cannabinoids and psychosis.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>79</volume>
<fpage>526</fpage>&#x02013;<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2016.01.011</pub-id><pub-id pub-id-type="pmid">26970363</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Showalter</surname><given-names>V. M.</given-names></name><name><surname>Compton</surname><given-names>D. R.</given-names></name><name><surname>Martin</surname><given-names>B. R.</given-names></name><name><surname>Abood</surname><given-names>M. E.</given-names></name></person-group> (<year>1996</year>). <article-title>Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.</article-title>
<source><italic>J. Pharmacol. Exp. Ther.</italic></source>
<volume>278</volume>
<fpage>989</fpage>&#x02013;<lpage>999</lpage>.<pub-id pub-id-type="pmid">8819477</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>M. A.</given-names></name><name><surname>Gao</surname><given-names>W. J.</given-names></name></person-group> (<year>2013</year>). <article-title>NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.</article-title>
<source><italic>Front. Cell Neurosci.</italic></source>
<volume>7</volume>:<issue>31</issue>
<pub-id pub-id-type="doi">10.3389/fncel.2013.00031</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonego</surname><given-names>A. B.</given-names></name><name><surname>Gomes</surname><given-names>F. V.</given-names></name><name><surname>Del Bel</surname><given-names>E. A.</given-names></name><name><surname>Guimaraes</surname><given-names>F. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice.</article-title>
<source><italic>Behav. Brain Res.</italic></source>
<volume>309</volume>
<fpage>22</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2016.04.042</pub-id><pub-id pub-id-type="pmid">27131780</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefansson</surname><given-names>H.</given-names></name><name><surname>Sigurdsson</surname><given-names>E.</given-names></name><name><surname>Steinthorsdottir</surname><given-names>V.</given-names></name><name><surname>Bjornsdottir</surname><given-names>S.</given-names></name><name><surname>Sigmundsson</surname><given-names>T.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Neuregulin 1 and susceptibility to schizophrenia.</article-title>
<source><italic>Am. J. Hum. Genet.</italic></source>
<volume>71</volume>
<fpage>877</fpage>&#x02013;<lpage>892</lpage>. <pub-id pub-id-type="doi">10.1086/342734</pub-id><pub-id pub-id-type="pmid">12145742</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stella</surname><given-names>N.</given-names></name><name><surname>Schweitzer</surname><given-names>P.</given-names></name><name><surname>Piomelli</surname><given-names>D.</given-names></name></person-group> (<year>1997</year>). <article-title>A second endogenous cannabinoid that modulates long-term potentiation.</article-title>
<source><italic>Nature</italic></source>
<volume>388</volume>
<fpage>773</fpage>&#x02013;<lpage>778</lpage>. <pub-id pub-id-type="doi">10.1038/42015</pub-id><pub-id pub-id-type="pmid">9285589</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>A.</given-names></name><name><surname>Baillie</surname><given-names>G. L.</given-names></name><name><surname>Phillips</surname><given-names>A. M.</given-names></name><name><surname>Razdan</surname><given-names>R. K.</given-names></name><name><surname>Ross</surname><given-names>R. A.</given-names></name><name><surname>Pertwee</surname><given-names>R. G.</given-names></name></person-group> (<year>2007</year>). <article-title>Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>150</volume>
<fpage>613</fpage>&#x02013;<lpage>623</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0707133</pub-id><pub-id pub-id-type="pmid">17245363</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>B. F.</given-names></name><name><surname>Gilliam</surname><given-names>A. F.</given-names></name><name><surname>Burch</surname><given-names>D. F.</given-names></name><name><surname>Roche</surname><given-names>M. J.</given-names></name><name><surname>Seltzman</surname><given-names>H. H.</given-names></name></person-group> (<year>1998</year>). <article-title>Comparative receptor binding analyses of cannabinoid agonists and antagonists.</article-title>
<source><italic>J. Pharmacol. Exp. Ther.</italic></source>
<volume>285</volume>
<fpage>285</fpage>&#x02013;<lpage>292</lpage>.<pub-id pub-id-type="pmid">9536023</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>A. R.</given-names></name></person-group> (<year>1946</year>). <article-title>Hashish.</article-title>
<source><italic>Experientia</italic></source>
<volume>2</volume>
<fpage>55</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/bf02163886</pub-id><pub-id pub-id-type="pmid">21016843</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzavara</surname><given-names>E. T.</given-names></name><name><surname>Li</surname><given-names>D. L.</given-names></name><name><surname>Moutsimilli</surname><given-names>L.</given-names></name><name><surname>Bisogno</surname><given-names>T.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Phebus</surname><given-names>L. A.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>59</volume>
<fpage>508</fpage>&#x02013;<lpage>515</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2005.08.019</pub-id><pub-id pub-id-type="pmid">16199010</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Buuse</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Prepulse inhibition of acoustic startle in spontaneously hypertensive rats.</article-title>
<source><italic>Behav. Brain Res.</italic></source>
<volume>154</volume>
<fpage>331</fpage>&#x02013;<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2004.02.021</pub-id><pub-id pub-id-type="pmid">15313020</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Ree</surname><given-names>J. M.</given-names></name><name><surname>Niesink</surname><given-names>R. J.</given-names></name><name><surname>Nir</surname><given-names>I.</given-names></name></person-group> (<year>1984</year>). <article-title>delta 1-Tetrahydrocannabinol but not cannabidiol reduces contact and aggressive behavior of rats tested in dyadic encounters.</article-title>
<source><italic>Psychopharmacology (Berl.)</italic></source>
<volume>84</volume>
<fpage>561</fpage>&#x02013;<lpage>565</lpage>. <pub-id pub-id-type="doi">10.1007/BF00431467</pub-id><pub-id pub-id-type="pmid">6098915</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Kayano</surname><given-names>Y.</given-names></name><name><surname>Matsunaga</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>I.</given-names></name><name><surname>Yoshimura</surname><given-names>H.</given-names></name></person-group> (<year>1996</year>). <article-title>Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids.</article-title>
<source><italic>Biol. Pharm. Bull.</italic></source>
<volume>19</volume>
<fpage>1109</fpage>&#x02013;<lpage>1111</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.19.1109</pub-id><pub-id pub-id-type="pmid">8874830</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollner</surname><given-names>H. J.</given-names></name><name><surname>Matchett</surname><given-names>J. R.</given-names></name><name><surname>Levine</surname><given-names>J.</given-names></name><name><surname>Loewe</surname><given-names>S.</given-names></name></person-group> (<year>1942</year>). <article-title>Isolation of a physiologically active tetrahydrocannabinol from <italic>Cannabis sativa</italic> Resin.</article-title>
<source><italic>J. Am. Chem. Soc.</italic></source>
<volume>64</volume>
<fpage>26</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1021/ja01253a008</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>A. H. C.</given-names></name><name><surname>Van Tol</surname><given-names>H. H. M.</given-names></name></person-group> (<year>2003</year>). <article-title>Schizophrenia: from phenomenology to neurobiology.</article-title>
<source><italic>Neurosci. Biobehav. Rev.</italic></source>
<volume>27</volume>
<fpage>269</fpage>&#x02013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1016/S0149-7634(03)00035-6</pub-id><pub-id pub-id-type="pmid">12788337</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>M. J.</given-names><suffix>Jr.</suffix></name><name><surname>Vandewater</surname><given-names>S. A.</given-names></name><name><surname>Taffe</surname><given-names>M. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol.</article-title>
<source><italic>Br. J. Pharmacol.</italic></source>
<volume>170</volume>
<fpage>1365</fpage>&#x02013;<lpage>1373</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12199</pub-id><pub-id pub-id-type="pmid">23550724</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zammit</surname><given-names>S.</given-names></name><name><surname>Allebeck</surname><given-names>P.</given-names></name><name><surname>Andreasson</surname><given-names>S.</given-names></name><name><surname>Lundberg</surname><given-names>I.</given-names></name><name><surname>Lewis</surname><given-names>G.</given-names></name></person-group> (<year>2002</year>). <article-title>Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.</article-title>
<source><italic>BMJ</italic></source>
<volume>325</volume>:<issue>1199</issue>
<pub-id pub-id-type="doi">10.1136/bmj.325.7374.1199</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuardi</surname><given-names>A. W.</given-names></name><name><surname>Hallak</surname><given-names>J. E.</given-names></name><name><surname>Dursun</surname><given-names>S. M.</given-names></name><name><surname>Morais</surname><given-names>S. L.</given-names></name><name><surname>Sanches</surname><given-names>R. F.</given-names></name><name><surname>Musty</surname><given-names>R. E.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Cannabidiol monotherapy for treatment-resistant schizophrenia.</article-title>
<source><italic>J. Psychopharmacol.</italic></source>
<volume>20</volume>
<fpage>683</fpage>&#x02013;<lpage>686</lpage>. <pub-id pub-id-type="doi">10.1177/0269881106060967</pub-id><pub-id pub-id-type="pmid">16401651</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuardi</surname><given-names>A. W.</given-names></name><name><surname>Morais</surname><given-names>S. L.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>F. S.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group> (<year>1995</year>). <article-title>Antipsychotic Effect of Cannabidiol.</article-title>
<source><italic>J. Clin. Psychiatry</italic></source>
<volume>56</volume>
<fpage>485</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">7559378</pub-id></mixed-citation></ref></ref-list></back></article>